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NOVEL MECHANISMS OF ANDROGEN RECEPTOR DEGRADATION BY
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ABSTRACT
Defining underlying molecular mechanisms exploited by cancer cells in their
development and progression provides a necessary foundation for experimental
therapeutics. The androgen receptor (AR) is a known therapeutic target for prostate
cancer (CaP) given its well-established role in both the development and progression of
CaP. The AR is a ligand activated transcription factor that regulates the expression of
many genes involved in proliferation and differentiation. Identifying agents that downregulate AR expression may elucidate mechanism(s) for selectively targeting the AR.
Two related agents of the natural products curcumin and vitamin E, curcumin analog 27
(ca27) and alpha-tocopheryl quinone (TQ), respectively were identified that downregulate AR protein expression in CaP cells. The purpose of this dissertation project was
to identify molecular pathways that contribute to AR down-regulation mediated by ca27
and TQ. While both ca27 and TQ down-regulate the AR, the kinetics of AR downregulation was distinct between the two agents. ca27’s down-regulation of AR protein
expression was observed within hours, while TQ effects were seen after two days.
Despite this difference, ca27 and TQ were found to have many similarities in their
v

mechanism of AR down-regulation. Both ca27 and TQ up-regulate CYP1A1 expression,
a known aryl hydrocarbon receptor (AHR) regulated gene. The AHR is a ligand activated
transcription factor known to be involved with detoxification and metabolic pathways.
However, the AHR itself did not appear to be regulating the observed effects on AR
expression mediated by ca27 and TQ. Interestingly, additional data suggests TQ might
serve as a ligand for the AHR (Chapter 4). Further, ca27 and TQ down-regulation of AR
protein expression was determined to be independent of proteasomal degradation and
transcriptional inhibition. Due to chemical structure considerations of ca27 and TQ, their
potential to modulate CaP cell reduction/oxidation parameters was examined. Both ca27
and TQ were shown to down-regulate AR protein expression through a cellular redox
mechanism, which was attenuated by the presence of the antioxidant N-acetylcysteine
(Chapter 2 and 3), respectively. This study identifies pathways critical to the mechanism
of action of ca27- and TQ-mediated AR protein down-regulation in human CaP cells and
demonstrates that these novel agents act though alterations in cellular redox.
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CHAPTER 1: INTRODUCTION

Brief Summary
With the high risk of developing prostate cancer (CaP) in men, and the possibility that
it will progress to a more advanced disease, development of novel targeted therapeutic
strategies for CaP is crucial. The androgen receptor (AR) plays a critical role in CaP
growth and progression. However, current strategies for CaP treatment eventually fail to
effectively inhibit the contribution of the AR to disease progression. Several natural
products have been identified as AR inhibitors in vitro but these agents often have
limitations for in vivo use. Two agents representative of natural products will be the focus
for this study, vitamin E (VE) and curcumin as experimental therapeutic agents for CaP.
The agents alpha-tocopheryl quinone (TQ) and curcumin analog 27 (ca27) were screened
for their potential in vitro anti-androgenic activity. Several human androgen-responsive
CaP cell lines were utilized in the characterization of TQ and ca27 actions. Both agents
were evaluated for their inhibition of cell proliferation and viability, AR activation and
AR expression. The focus of this study was to identify TQ and ca27’s mechanism(s) of
AR protein down-regulation. Several potential mechanisms of TQ and ca27’s AR downregulation were systematically identified and evaluated. These potential mechanisms
included, transcriptional inhibition, proteasomal degradation, aryl hydrocarbon receptor
(AHR) mediated degradation and pathways involving oxidative stress. This study
identifies a potential mechanism of TQ and ca27’s AR down-regulation. Inhibiting the
expression of the AR may be an effective therapeutic strategy for prostate cancer. TQ’s
and ca27’s actions on AR down-regulation may in part have similar activities, but these
1

two agents will be presented separately in this dissertation. The results of this study may
provide insight into therapeutically useful mechanisms of AR protein down-regulation.
The prostate gland, prostate cancer, and the androgen receptor
The prostate is a male sex accessory gland located at the base of the bladder behind
the pubic bone just in front of the rectum. The prostate wraps around the urethra, the
urethra is a tube that carries urine from the bladder to the penis (1). Its primary
physiologic role is the addition of secretions to sperm during ejaculation. Androgens such
as testosterone and dihydrotestosterone (DHT) are essential for normal prostate
development and function. Both testosterone and DHT exert their effects through their
binding of the AR (2). The AR is a transcription factor that regulates genes involved in
masculinization during development, reproduction, muscle development and prostate
growth (3). The AR is required for normal prostate development and also has a
significant role in CaP.
CaP is the second most frequently diagnosed malignancy and the sixth leading cause
of cancer death in men world-wide (4). The incidence rates for prostate cancer vary
greatly world-wide, with the highest rates recorded for more developed countries (4). In
the United States (US), CaP accounts for 12% of cancer incident cases (5). Age, ethnicity
and family history are major risk factors for developing CaP. The progression of CaP
varies among individuals; while some CaP grow slowly and remain confined to the
prostate gland others are more aggressive and can spread quickly. CaP is initially
sensitive to androgen deprivation therapy but usually progresses to a castration-resistant
disease. This progression can be attributed to the activation and signaling of the androgen
receptor (6,7).
2

The AR or NR3C4 is a member of the steroid hormone receptor family of liganddependent nuclear receptors. The activity of the AR is essential for normal prostate
development and is an important mediator of CaP growth and development. One of the
AR roles is as a transcription factor for several genes involved in the development and
differentiation of the prostate (8). The AR is activated by androgens such as testosterone
or its more active metabolite, DHT. Most (90-95%) testosterone in men is produced by
the Leydig cells of the testies, with additional androgens or androgen precursors
produced by the adrenal gland (9). DHT is converted from testosterone by the enzyme 5α reductase (10,11). Upon ligand binding, the AR releases from chaperone proteins such
as heat shock protein 90 (HSP90), homodimerizes, and is phosphorylated. The AR is then
free to translocate into the nucleus and bind co-regulators leading to its activity as a
transcription factor (8,12). Specific recognition sequences known as androgen receptor
response elements (ARREs) in the promoter and enhancer regions of target genes, such as
prostate specific antigen (PSA) gene, are recognized by the AR (Fig. 1A) (11). Although
inhibition of androgen production and AR activity are currently used as therapeutic
targets for CaP, targeting the AR itself may prove to be a more effective therapeutic
strategy.
Androgen deprivation therapy targeting the synthesis of testicular androgens such
as the use of luteinizing hormone-releasing hormone (LHRH) analogs or surgical
castration increases the survival of CaP patients but it is not curative for the disease
(13,14). Two possible explanations are that either there is an incomplete ablation of
androgen allowing for continued AR activation or the receptor can bypass the androgen
depleted environment in an alternative fashion. Both are possible explanations since, after
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androgen ablative treatment, remaining residual of circulating testosterone and 5αdihydrotestosterone (DHT) can be detected (15). The importance of the AR function in
CaP is evident by the de novo autocrine intra-tumoral synthesis of androgens from
cholesterol. One of the key enzymes in this production of androgens is CYP17. CYP17
activity can be inhibited by the irreversible inhibitor abiraterone acetate (i.e. Zytiga) or
the antifungal agent ketoconazole (Fig.1A) (7). For recurrent disease, the low
concentrations of androgens can be sufficient to activate a functional AR. The inhibition
of the conversion of testosterone into DHT has been identified as another strategy for
CaP. Inhibiting DHT expression can be achieved by inhibition of the enzymes 5-α
reductase type 1and 2. Two inhibitors are currently available finasteride, a type 1 5-α
reductase inhibitor and dutasteride, a dual 5-α reductase inhibitor (16). However, these
inhibitors target the production of

DHT thereby inhibiting activation of the AR

indirectly. The inclusion of other treatment options such as the nonsteroidal AR
antagonists biclutamide (i.e. Casodex) and MDV3100 directly target the AR (Fig. 1A)
(7,17). Biclutamide and MDV3100 competitively bind the ligand binding domain of the
AR, inhibiting natural ligand binding (7). Both of these treatments inhibit the AR, but
they do not down-regulate AR expression. However, studies have demonstrated that most
biclutamide resistant CaP still express AR protein (18,19). This insufficient suppression
of AR can lead to adaptation such as reduced selectivity for ligands capable of AR
activation, increased activation of AR signaling pathways and increased expression of
AR mRNA and protein (13,19,20). CaP therapeutics down-regulating AR expression may
provide a novel strategy that would bypass adaptive mechanisms and inhibit
advancement of the disease.

4

The human AR gene is located on the X-chromosome (Xq11-q12), and is
therefore present as a single copy in men. Since there is a single copy of the AR, any gene
mutations could lead to phenotypic manifestation (21). The AR’s first exon codes for the
amino-terminal domain that contains several regions of repetitive DNA sequences. These
regions code for polyglycine, proline and glutamine stretches, which have different
significances in AR function (Fig 1B). For instance, the length of the polyglutamine
stretch has been linked to the neurodegenerative disease, named Kennedy’s disease, or
spinal and bulbar muscular atrophy (SMBA) (21,22). It has been demonstrated that the
extended poly-glutamine stretch (greater than 40 glutamines) induces a misfolded
confirmation of the AR that leads to the formation of intracellular aggregates (22). The
human AR protein contains approximately 919 amino acids resulting in an approximately
110kDa protein. However, this length and size can vary due to poly-glutamine and/or
poly-glycine stretches. The AR has a centrally located DNA binding domain (DBD)
consisting of two zinc-finger motifs (Fig. 1B) (21). Also, it features a hinge region which
connects the DBD to the ligand binding domain (LBD) (Fig. 1B) (23). The importance of
the LBD in activation and stability of the AR is through the interaction with ligands and
multiple chaperones. It has recently been demonstrated that a truncated AR lacking the
LBD was constitutively active (24). The LBD is critical for preventing the non-selective
activation of the AR.
The expression and function of the AR can be regulated through multiple cellular
pathways. The complexity of targeting the AR requires a broader understanding of the
AR’s role in normal development, as well as various disease etiologies. The investigation
of ca27 and TQ provides a means to identify mechanisms of directly targeting the AR
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protein itself. The goal of this study was to identify novel mechanisms of AR protein
down-regulation that may have relevance in the prevention or treatment of prostate
cancer.

Fig. 1A

Fig. 1B

6

Fig. 1: Diagram of the AR activation pathway and AR protein structure. A, illustrates
activation of the AR by DHT and demonstrates selective agents that target multiple steps
in the AR activation pathway. Fig. 1A, adapted from Ref. 7. B, represents AR protein
structure with several domains indicated. Fig.1B Image adapted from Ref. 21.
Curcumin, ca27, and ca27’s down-regulation of the AR
Curcumin, (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione,
a diferuloylmethane compound (Fig. 2), isolated from the plant Curcuma longa has been
proposed as a cancer chemopreventative agent (25). Previous studies have shown the
potential of curcumin to inhibit metastasis, angiogenesis and proliferation in prostate
cancer cell lines (26,27). Curcumin has also been shown to reduce cellular proliferation,
AR transactivation and inhibit AR expression in CaP cells (28). However, despite the
inhibitory actions of curcumin in CaP cells in vitro, it has demonstrated limitations in
vivo due to a low bioavailability, warranting the search for more bioactive analogs (29).
Initial screenings of a combinatorial chemical library based on the structure of curcumin,
synthesized by Drs. Vander Jagt’s (Department of Biochemistry and Molecular Biology,
University of New Mexico) and Deck’s (Department of Chemistry and Chemical
Biology, University of New Mexico) laboratories, identified curcumin analogs that were
able to inhibit transcription factors involved in cancer progression such as activator
protein-1 (AP-1) and nuclear factor kappa B (NFkB) (30,31). Several analogs of this
library were screened for their anti-androgenic activities. The primary screen of these
analogs was designed to evaluate the inhibition of CaP cell proliferation and viability.
These analogs were further tested for their ability to inhibit AR activity and then
validated for their inhibition of AR protein expression. This screening procedure resulted
7

in the identification of curcumin analog 27 (ca27) as a potential lead agent for identifying
mechanisms of AR down-regulation. ca27 effectively inhibits AR activity and expression
in multiple human prostate cancer cells. Identification of ca27’s actions in determining
the mechanism of AR inhibition could provide insight into novel approaches for downregulating the AR.
Several modifications were made to curcumin’s chemical structure in the synthesis of
ca27 (Fig. 2). ca27 contains an α, β-unsaturated carbonyl, instead of the diketone or enol,
the seven carbon linker between the aryl groups of curcumin was reduced to five, the
methoxy groups were removed and the phenolic hydroxyl groups of the aromatic
moieties were placed at the ortho-positions (Fig. 2). These modifications demonstrated
distinct differences in the cellular activity between ca27 and curcumin. ca27 significantly
down-regulated AR protein expression within 3 hours, while curcumin did not inhibit AR
protein expression in my studies (Chapter 2). ca27 down-regulation of AR protein
expression may be through its activity as a pro-oxidant. Agents that induce oxidative
stress, such as piperlogumine, have been reported to induce selective cell death in
multiple cancer cell lines with little effect, in normal cells (32). To determine if the
induction of oxidative stress by ca27 resulted in the down-regulation of AR protein, cells
were treated with ca27 and the anti-oxidant, glutathione analog, N-acetylcysteine (NAC)
(33,34). NAC significantly prevented AR down-regulation upon ca27 treatment (Chapter
2). Thus, the increase in oxidative stress may be part of ca27’s mechanism of AR downregulation.
Cellular oxidative stress and the generation of reactive oxygen species (ROS) play
important roles in the regulation of cell signaling and cell survival. Low to moderate
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levels of oxidative stress may function as signals to promote cell proliferation and
survival. However, sudden or prolonged periods of cellular oxidative stress can induce
cell death (35). The transcription factor nuclear factor E2-related protein (Nrf2) regulates
the expression of several cytoprotective enzymes including antioxidant and phase II
detoxifying enzymes (36). Transcriptional activation of Nrf2 is through the activation of
the Keap1/Nrf2/ARE pathway. Keap1 (Kelch-like ECH-associated protein 1) is a
repressor protein of Nrf2 transcriptional activity. Keap1 retains Nrf2 within the
cytoplasm and promotes its ubiquitination and proteasomal degradation. An accepted
explanation of this regulatory mechanism is provided by agents or inducers that react
with sulfhydryl groups and modify the highly reactive cysteine residues of Keap1
disrupting its interaction and repression of Nrf2 (37). Upon release from Keap1, Nrf2
drives the transcription of antioxidant or electrophile response regulated genes. The
transcriptional activity of Nrf2 can be mediated through pharmacological agents, redox
potential and natural products (38). Transcriptional activation of Nrf2 can be monitored
as an indirect means of agents that perturb cellular redox homeostasis.
Glutathione is an endogenous antioxidant whose expression can be mediated
through the activation of Nrf2. Two genes regulated by Nrf2 are the enzymes required for
glutathione synthesis, γ-glutamate cysteine ligase and glutathione synthetase (39). One of
the major antioxidant defenses of the cell is endogenous thiols (sulhydryl containing
compounds) such as glutathione and thioredoxin (34,35). Glutathione is the primary nonprotein thiol in cells and exists in two redox forms, reduced glutathione (GSH) and
oxidized glutathione disulfide (GSSG). Cells can excrete GSSG or reduce it back to GSH
through the NAD(P)H dependent activity of glutathione reductase (35). The oxidation of
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glutathione can be catalyzed by the selenoprotein glutathione peroxidase (GPx). GPx
detoxifies reactive hydrogen peroxide and other hydroperoxides into molecular oxygen
and water by the oxidation of two thiol groups into a disulfide (e.g. GSSG) (35,40). GSH
cellular content ranges from 1-10 mM depending on cell type and is critical for redox
balance and normal cellular function (33,35). GSSG can be reduced back into GSH by
the enzyme glutathione reductase and the cofactor NADPH. GSH synthesis is a two-step
enzymatic process catalyzed by γ-glutamate cysteine ligase (γ-glutamylcysteine
synthetase) and GSH synthetase. The antioxidant activity of GSH is partially through its
role as an endogenous thiol. NAC also contains a thiol group and has been reported to be
a precursor of L-cysteine and reduced glutathione (33,34). The antioxidant activity of
NAC may in part inhibit the activity of ca27. ca27 evokes cellular redox response
pathways and the generation of ROS. ca27’s pro-oxidant activity may be required for the
down-regulation of the AR. ca27’s down-regulation of the AR is attenuated by the
presence of NAC.

Fig. 2: Structures of curcumin and curcumin analog 27 (ca27).
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Vitamin E, α-tocopherylquinone (TQ) and TQ’s down-regulation of the AR
Vitamin E (VE) is a family of dietary agents (e.g. α-,β-,γ-,δ-tocopherols and tocotrienols),which were first described 1922 by Evans and Bishop (41) as an accessory
food factor essential for reproduction of rats. VE exists in eight different naturally
occurring forms which all feature a chromanol ring with a hydroxyl group and a 16carbon hydrophobic phytyl side chain (Fig. 3). The α-tocopherol (α-T) isoform is a
lipophilic antioxidant that prevents free radical production and lipid peroxidation
(42).The chromanol ring moiety is responsible for α-T antioxidant activity and the
lipophilic phytyl chain determines it retention in membranes and subcellular distribution
(43).
α-T is the most bioactive of the VE isoforms and shown to reduce the incidence and
mortality of prostate cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention
(ATBC) study. This was a large prevention trial conducted in Finnish men, who were
randomized to receive 50 mg of DL-α-tocopheryl acetate for 5 to 8 years. The outcome of
this trial showed a decrease in CaP incidence (32%) and mortality (41%) in men that
were cigarette smokers who received α-T (44). This chemopreventive activity may be
unique to α-T since other studies have demonstrated that the intake of the β-, γ-, and δtocopherol isoforms are not associated with the inhibition prostate cancer risk (45). α-T’s
actions as a CaP chemopreventive agent has been highly controversial due in part to the
outcome of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). This phase
III, randomized, placebo-control trial was initiated in 2001 and was terminated in 2008
due to increases in potentially problematic side effects. The two major problematic trends
reported were the increase in type II diabetes mellitus in the selenium cohort and an
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increase in CaP incidence in the VE cohort; neither of these trends were found to be
statistically significant (46). The discrepancy between the outcomes of the ATBC and
SELECT trials may be due to the selective cohort of men who were heavy smokers in the
ATBC trial compared to the majority of men who were non-smokers in the SELECT
trial. In an alternative experimental setting, Wurzel, H et al. (47) conducted an in vivo
study which exposed rats to chronic cigarette smoke and α-T for 65 weeks. In the
experimental group, they found high levels of TQ in the bronchoalveolar lavage fluid
demonstrating that smoke-exposed animals generated a larger amount of oxidative
products (47). In my studies, there are distinct differences between TQ and α-T actions
on CaP cells and on the AR. In contrast to α-T, I found TQ to inhibit AR activity and
expression in human CaP cells (Chapter 3).
There is a large degree of variation in the potential cellular actions between the
tocopherol forms and their corresponding quinone forms. In a review by David Cornwell
and JiyanMa (48), the comparison of γ-tocopherol quinone (γ-TQ), δ-tocopherol quinone
(δ-TQ) and α-TQ chemical activities were evaluated from multiple studies. Both γ-TQ
and δ-TQ were found to be potent arylating electrophiles leading to Michael adduct
formation with nucleophiles such as the thiol group in glutathione (48). However, α-TQ
(TQ) was found to be a non-arylating quinone electrophile with distinct cellular and
chemical properties from the arylating quinone electrophiles γ-TQ and δ-TQ in their
studies. Arylating quinone electrophiles are highly cytotoxic agents that can induce
apoptosis and result in cell death. Both γ-TQ and δ-TQ were found to have profound
effects on cell viability and morphology in comparison to α-TQ in a human acute
lymphoblastic leukemia cell line (49). In a follow-up study, γ-TQ (not α-TQ) was found
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to induce endoplasmic reticulum stress (ER stress) pathways due to its actions as an
arylating electrophile, which may lead to Michael adduct formation with protein disulfide
isomerases (50). These studies have evaluated the actions of α-TQ and γ-TQ in a very
short treatment time (50µM for 24h) (49,50). In my studies, α-TQ’s actions on AR
protein down-regulation and induction of ER stress pathways were time-dependent
(Chapter 3). Further, TQ induces oxidative stress and down-regulation of the AR that
may dependent on its activity as a pro-oxidant. The reactivity of the quinone forms
described are very different, but their cellular actions may provide further insight into αTQ’s mechanism of AR down-regulation.
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R2

R3

α

CH3

CH3

CH3

β

CH3

H

CH3

γ

H

CH3

CH3

δ

H

H

CH3

Fig. 3: Structures of α-, β-, γ-, δ-tocopherols and -tocotrienols within the VE family.
Table 1: R-groups represent the indicated group at various positions for the multiple
forms. Adapted from Ref. 48.
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Fig. 4: Oxidative conversion of α-tocopherol (VE) into the metabolite α-tocopheryl
quinone (TQ).
The role of the AHR and other agents on AR down-regulation
Environmental toxins such as the polycyclic aromatic hydrocarbon benzo(a)pyrene
(B(a)P) exert their toxic effects through the activation of the aryl hydrocarbon receptor
(AHR) (51). The AHR is a well-characterized ligand activated transcription factor which
belongs to the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family. The AHR
regulates several genes involved in xenobiotic metabolism and detoxification pathways
such as cytochrome P450 1A1 (CYP1A1), CYP1B1 and glutathione-S-transferase (52).
Over the last several years, studies conducted by Dr. Kato and colleagues (52,53) have
elucidated a novel cellular role of the AHR independent from its transcriptional activity.
The AHR can act as an adaptor protein for E3 ubiquitin ligases which enhances the
proteasomal degradation of steroid hormone receptors such as the estrogen receptor and
AR (52,53). This novel action of the AHR may explain some of its toxicological and
physiological effects. In this dissertation, ca27 and TQ were evaluated for activation of
the AHR and the AHR’s potential role in AR protein down-regulation.
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The AR’s expression is regulated post-translationally by the ubiquitin/proteasome
system. Ubiquitylation is based on the attachment of ubiquitin to the lysine residues on a
target protein (e.g., AR) and involves the action of three ubiquitin ligases E1, E2 and E3.
These three ligases work in a defined order to ubiquitylate the AR, which then becomes
degraded by the proteasome (12,54). AR expression can be regulated by 26S proteasomal
degradation either in the presence or absence of ligand. The inactive AR is retained in the
cytoplasm bound to a multichaperone complex including HSP90: this interaction prevents
the degradation of the AR (54). Agents such as genistein or geldanamycin disrupt the AR
and chaperone interaction resulting in AR proteasomal degradation (55,56). To identify
TQ and ca27’s mechanism(s) of AR protein down-regulation I evaluated the role of the
AHR on AR down-regulation. In 2004, Lin, et al. (57) demonstrated that the AHR
agonist B(a)P could inhibit AR protein expression in the human adenocarcinoma cell line
H1355. In elucidating the mechanism of AHR activation and AR down-regulation
Ohtake, et al. (53) demonstrated activation of the AHR by the AHR agonist 3methylcholanthrene (3-MC) which led to the proteasomal degradation of the AR. I
showed that treatment of CaP cells with B(a)P led to the proteasomal degradation of AR
protein (Chapter 4). However, TQ and ca27’s down-regulation of the AR was not
attenuated by the knock-down of AHR expression. Although, the AHR was not found to
be a critical contributor to TQ or ca27’s mechanism of AR down-regulation, the
interaction of the AHR and AR may provide further insight into mechanisms of
endocrine disruption.
The importance of AR function and expression in CaP has led to the development
of multiple strategies that lead to AR down-regulation. The identification of AR
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inhibitory mechanisms by natural products such as genistein can be utilized in the
development of analogs designed to enhance activity or potentially overcome limitations.
As discussed previously targeting down-regulation of AR protein expression can be
accomplished by the agent genistein which distrupts AR and HSP90 interaction resulting
in AR proteasomal degradation (56). This strategy for down-regulating the AR can be
utilized in diseases other than CaP where the AR is a target. The genistein analogs, 17allylamino-17-demethoxygeldanamycin (17-AAG) or 17-(dimethlaminoethlamino)-17demethoxygeldamycin (17-DMAG) are being investigated for their beneficial role in
inhibiting mutant aggregate prone AR found in SBMA (58,59). The recent identification
of andrographolide an inhibitor of interleukin-6 has recently been identified to disrupt the
binding of HSP90 and AR and promote AR proteasomal degradation (60). These
strategies require a functional proteasome and a continued AR/HSP90 complex but
disruption of proteasomal function or alternative AR forms could limit the potential of
these agents.
Other natural products such as VE have shown potential benefits for CaP
prevention but are controversial. VE analogs such as VE succinate have been reported to
inhibit CaP cell growth, inhibit PSA expression and down-regulate AR protein expression
(61). The green tea polyphenol, (-)-epigallocatechin gallate (EGCG) has been previously
reported to inhibit AR activation and AR expression in CaP cells (62). However concerns
about bioavailability of VE succinate and ECGC limit the use of these agents. Natural
products provide a meaningful foundation for the development of experimental
therapeutic agents.

16

The identification of variant forms of the AR provides potential targets for the
inhibition of CaP. In CaP, splice variants of the AR have been identified and their role in
CaP development and progression are still being determined (63). The constitutive
activation of splice variants lacking domains (i.e. LBD) critical for the HSP90/AR
interaction would be resistant to previously mentioned strategies. Therefore alternative
approaches for inhibiting AR expression are currently being investigated. Agents such as
Nigericin are being investigated for their inhibitory actions of multiple variant AR
mRNA expression (64). The strategy of inhibiting AR mRNA expression is also utilized
by generation of AR antisense agents. Recently Zhang, Y et al. (65) has demonstrated the
use of a locked nucleic acid-based antisense oligonucleotide, EZN-4176. EZN-4176
demonstrates selective down-regulation of AR mRNA in animal models (65). EZN-4176,
potential activity in vivo is a promising approach but still requires verification this is a
deliverable approach in humans. The down-regulation of AR expression is a meaningful
target in multiple diseases including CaP. Identifying novel mechanisms regulating AR
expression will provide insight and opportunity for the development of therapeutic
agents.

Dissertation Objectives:
The purpose of this study was to identify TQ and ca27’s mechanism of AR downregulation. The following objectives outline my investigations of ca27 and TQ.
1. Characterize the anti-androgenic activity of TQ and ca27 in comparison to VE
and curcumin
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a. Determine dosage range and time course for TQ and ca27 to effectively
inhibit CaP cell proliferation and viability
b. Determine concentrations of TQ and ca27 that effectively inhibit AR
activity as measured by an AR reporter assay and expression of an
endogenous AR regulated gene (e.g., PSA)
2. Characterize the effect of ca27 and TQ on AR expression in human CaP cells
a. Determine the inhibitory effects of agents on AR mRNA expression
b. Determine the effects of ca27 and TQ on AR protein levels
c. Determine the kinetics of AR down-regulation by TQ and ca27
3. Identify potential mechanisms of ca27 and TQ’s down-regulation of AR protein
expression
a. Determine if AR protein down-regulation is due to inhibition of AR
mRNA expression
b. Determine if ca27 and TQ induce proteasomal degradation of the AR
c. Determine if activation of AHR activity by ca27 and TQ leads to AR
protein down-regulation
d. Determine if TQ and ca27 induce oxidative stress and if this contributes to
AR down-regulation

Summary
Men have a one in six risk of developing CaP over their lifetime. While current
therapies successfully reduce the progression of CaP for the majority of men, the
remainder may receive treatment targeting AR activation. The AR is an important
18

mediator of CaP growth and progression. Therefore, identifying mechanisms to downregulate AR protein may be useful in developing novel strategies to treat advanced
prostate cancer. In the following studies, we investigated two agents that possess antiandrogenic activities in CaP cells. These novel agents (i.e., TQ and ca27) were further
investigated for their mechanisms of AR down-regulation and induction of oxidative
stress. Overall, the hypothesis is posed that TQ and ca27 are pro-oxidants that this
contributes to the down-regulation of AR. Agents capable of down-regulating AR protein
will facilitate the elucidation of novel mechanisms of AR inhibition and potentially lead
to the development of novel CaP therapies.
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CHAPTER 2: THE CURCUMIN ANALOG CA27 DOWN-REGULATES
ANDROGEN RECEPTOR THROUGH AN OXIDATIVE STRESS MEDIATED
MECHANISM IN HUMAN PROSTATE CANCER CELLS

Abstract
Background The androgen receptor (AR) plays a critical role in prostate cancer
development and progression. Therefore, the inhibition of AR function is an established
therapeutic intervention. Since the expression of the AR is retained and often increased in
progressive disease, AR protein down-regulation is a promising therapeutic approach
against prostate cancer. We show here that the curcumin analog (ca27) down-regulates
AR expression in several prostate cancer cell lines.
Methods ca27 at low micromolar concentrations was tested for its effect on AR
expression, AR activation, and induction of oxidative stress in human LNCaP, C4-2 and
LAPC-4 prostate cancer cells.
Results ca27 induced the down-regulation of AR protein expression in LNCaP, C4-2 and
LAPC-4 cells within 12 hours. Further, ca27 led to the rapid induction of reactive oxygen
species (ROS). To further support this finding, ca27 treatment led to the activation of the
cellular redox sensor NF-E2-related factor 2 (Nrf2) and the induction of the Nrf2regulated genes NAD(P)H quinone oxidoreductase 1 and aldoketoreductase 1C1. We
show that ROS production preceded AR protein loss and that ca27 mediated downregulation of the AR was attenuated by the antioxidant, N-acetyl cysteine.
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Conclusions ca27induces ROS and mediates AR protein down-regulation through an
oxidative stress mechanism of action. Our results suggest that ca27 represents a novel
agent for the elucidation of mechanisms of AR down-regulation which could lead to
effective new anti-androgenic strategies for the treatment of advanced prostate cancer.
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Introduction
The AR is a ligand activated steroid hormone receptor and a key regulator of both
normal prostate development and function (1). The AR plays a critical role in both
prostate cancer development and progression (2). Consequently, the current therapeutic
strategies for prostate cancer intervention, such as androgen ablation therapy (3) target
the inhibition of AR function. Such treatment, in its most aggressive form is based on
combinations of androgen synthesis suppression and AR inhibition (4). Fortunately, the
majority of men undergoing androgen ablation therapy successfully respond to this
therapy. However, the median response to androgen ablation is typically less than two
years, and patients recur with progressive disease within 12-18 months, developing
androgen ablation resistant cancer (5). This advanced stage is characterized by the
continuous expression and function of the AR in the presence of low concentrations of
androgens (6-7).Under these conditions, the AR supports prostate cancer cell survival, as
the down-regulation of AR protein in androgen ablation resistant prostate cancer cells and
animal models leads to cell growth inhibition and death (8-9). These findings emphasize
the importance of the AR and its signaling axis for all stages of prostate cancer, thus
rendering it a prominent and promising target (2,4,10-11). Therefore, the identification of
chemical agents that down-regulate AR expression by known or novel mechanisms
warrant further investigation for development as a novel prostate cancer therapeutic
approach.
We have previously reported the synthesis of an enone analog chemical library of the
natural diphenolic product curcumin (diferuloylmethane, or 1,7-bis(4-hydroxy-3methoxyphenyl)-1,6-heptadien-3,5-dione) (12-14). In the present study, we report on a
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compound from this library, curcumin analog 27 (ca27) (14). ca27 belongs to a series of
symmetrical diphenolic analogs which in contrast to curcumin feature a shorter 5-carbon
unsaturated linker with a single carbonyl group (Fig. 1A)(14). The two phenolic rings of
ca27 feature symmetrical ortho-hydroxyl groups. The carbon linker retains the character
of an α,β-unsaturated ketone which has properties of a Michael acceptor for strong
nucleophilic groups (15). Structure analysis relationship (SAR) studies reported by
several other groups indicate that this property is responsible for conferring the antiproliferative abilities of curcumin analogs (15-16).
In the current study we have demonstrated that ca27 mediates the down-regulation of
AR protein expression and activity. We further provide a potential mechanism of action
for ca27 on the AR by studying its effect on the redox status in prostate cancer cells. We
show that ca27 induced the generation of intracellular reactive oxygen species (ROS) by
the 2’,7’-dichlorofluorescein diacetate (DCF) assay. In support of this finding, ca27
increased the activation of the cellular redox sensor, NF-E2-related factor 2 (Nrf2),
followed by expression of the Nrf2 regulated detoxification genes, NAD(P)H quinone
oxidoreductase 1 (NQO1)and aldoketoreductase 1C1 (AKR1C1). Because the antioxidant
(electrophilic) response element regulation is associated with Nrf2 activation the two
concepts were used interchangeably and will be referred to as Nrf2 activity. Finally, we
show that the antioxidant N-acetyl cysteine (NAC) abrogates ca27 mediated AR downregulation, which provides further support that ca27 induced AR protein loss is mediated
by oxidative stress. Importantly, ca27 and similar curcumin analogs represent a novel
class of agents for the elucidation of mechanisms of AR down-regulation in prostate
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cancer cells which could lead to effective new anti-androgenic strategies for the treatment
of advanced prostate cancer.

Materials and Methods
Chemical Reagents
The curcumin analog 27 (ca27) (1,5-Bis(2-hydroxyphenyl)-1,4-pentadien-3-one) was
synthesized and characterized as previously described (14). This diphenolic chemical was
solubilized in 100% dimethyl sulfoxide (DMSO) stored protected from light at 4°C. The
synthetic androgen methyltrienolone (R1881) was from Perkin Elmer/NEN Life Science
Products (Boston, MA). MG132, N-acetyl-L-cysteine (NAC) and Actinomycin D (Act D)
were from Sigma Chemical Co. (St. Louis, MO).
Cell Culture and Treatment Protocols
The human prostate cancer cell lines LNCaP (American Type Culture Collection,
Manassas, VA), C4-2 (gift from Dr. G.N. Thalmann, University of Bern, Switzerland)
and a variant of the LAPC-4 (acquired from Dr. George Wilding, University of
Wisconsin Paul P. Carbone Comprehensive Cancer Center) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 5%
heat-inactivated fetal bovine serum (FBS) and streptomycin-penicillin antibiotics
(DMEM/FBS). To evaluate androgenic responses cells were cultured in DMEM
containing 4% charcoal-stripped FBS and 1% heat-inactivated FBS (DMEM/CSS). All
cells were maintained at 37°C in a humidified 5% CO2 atmosphere. ca27 was added to
the cells for the indicated lengths of time and final concentrations. Vehicle controls never
amounted to a final concentration of>0.1% DMSO.
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Cell Proliferation and Viability Assays
Cells were plated in quadruplicate in a 12-well tissue culture plates (Invitrogen,
Carlsbad, CA) in DMEM/FBS and treated with ca27 at the indicated final concentrations
for 96 hours. After cell detachment in 2.5% Trypsin/EDTA (Invitrogen, Carlsbad, CA),
cell proliferation was determined by total cell count in a hemacytometer by light
microscopy. Viability was determined by trypan blue dye exclusion (0.4%; Sigma, St.
Louis, MO). Results are expressed as percent of vehicle control.
Promoter Activation Assays
Cells were cultured in quadruplicate in 24-well plates (Invitrogen, Carlsbad, CA) in
DMEM/CSS. After 48 hours, cells were co-transfected with a reporter plasmid carrying a
mouse mammary tumor virus (MMTV) promoter regulating luciferase cDNA expression
(17) and a control plasmid carrying a thymidine kinase (TK) promoter regulating Renilla
luciferase cDNA expression (Promega, Madison, WI) using Lipofectamine 2000
transfection agent (Invitrogen, Carlsbad, CA). Twenty-four hours post-transfection cells
were treated with ca27 at the indicated concentrations for 24 hours. After stimulation
with 1 nMR1881 for 6 hours, whole cell extracts were generated using Cell Culture Lysis
Reagent (Promega, Madison, WI). Luciferase activity was measured using the Luciferase
Assay Substrate kit (Promega, Madison, WI) and relative luciferase units determined on a
Perkin Elmer Victor3V 1420 counter and analyzed using Wallac 1420 software (Perkin
Elmer, Turku, Finland). Cells were cultured as described above and co-transfected with a
reporter plasmid carrying an antioxidant response element promoter regulating luciferase
cDNA expression, pNQO1hARE (18) and the control TK promoter plasmid. Forty eight
hours post-transfection, cells were treated with the indicated concentrations of ca27 for
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16 hours. Luciferase activity was determined as outlined above. Normalized luciferase
expression is expressed as a percent of vehicle control.
AR activation was further measured using the Multifunctional Androgen Receptor
Screening (MARS) Assay (19). Androgen independent PC-3human prostate cancer cells
were co-transfected with a wild-type AR expressing plasmid and a plasmid carrying an
MMTV promoter containing an AR response element driving destabilized enhanced
green fluorescent protein (dsEGFP). In this assay, AR activation is stimulated by R1881
at 1 nM. Images of fluorescent cells were captured using an Olympus IX70inverted
fluorescent microscope and fluorescence was quantified by ImageJ software (20). The
number of fluorescent cells was expressed as percent of control.
Messenger RNA (mRNA) Expression Analysis by Quantitative (Real Time) Reverse
Transcriptase Polymerase Chain Reaction (qRT-PCR)
Cells were cultured in quadruplicate in 24-well plates (Invitrogen, Carlsbad, CA) in
DMEM/FBS and treated with ca27 for 3 or 12 hours at the indicated concentrations.
Total RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA) and cDNA
was prepared using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). PCR was performed using an Applied Biosystems 7900HT
Fast Real-Time PCR System (Carlsbad, CA). PCR cycling parameters were 95˚C for 10
minutes followed by 40 cycles of 95˚C for 15 seconds, and 60˚C for 1 minute. Forward
and reverse primers for the AR and the normalization control gene glyceraldehyde 3phosphate dehydrogenase (GAPDH) were available in the QuantiTect Primers Assays
from Qiagen (Valencia, CA). Forward and reverse primers for PSA, NQO1, AKR1C1
and MafG were purchased from Integrated DNA Technologies (Coralville, IA). PSA
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forward primer sequence is 5’-CGCTGGACAGGGGGCAAAA-3’ and the reverse
primer sequence is 5’-ACAAGTGGGCCCCCAGAATCA-3’. NQO1 forward primer
sequence is 5’-TGAGCTCGAGCCCCGGACTGCACCAGA-3’ and the reverse primer
sequence is 5’-CTACCGCGGCAAGTCAGGGAAGCCTGGAAAGAT-3’. AKR1C1
forward primer sequence is 5’-GATGGCCTAAACAGAAATGTGCGAT-3’ and the
reverse primer sequence is 5’-GGATAATTAGGGGGGCCAGCAA-3’. MafG forward
primer sequence is 5’-GCTGTGCCCCCGGGTTATGA-3’ and the reverse primer
sequence is 5’-CCGTCAGGCTGGTGCCATTCT-3’. AR, PSA, NQO1, AKR1C1 and
MafG mRNA expression levels normalized to GAPDH were determined using the ΔΔCt
method and are shown relative to control.
Reactive Oxygen Species(ROS) Detection by DCF
Cells were cultured in 96-well plates (Corning Inc., Corning, NY) in DMEM/FBS for
48 hours and then treated with ca27 for 1 hour at the indicated concentrations. Cells were
analyzed for the formation of ROS by use of the fluorescent probe, 2’,7’dichlorofluorescein diacetate (DCF) (Invitrogen, Carlsbad, CA) as described by Basu et
al.(21). DCF fluorescent units per well were measured 1 hour after DCF addition. DNA
content per well was measured by the Hoechst 33258 dye (Sigma, St. Louis, MO) (22).
Fluorescence measurements for both the DCF assay and Hoechst dye were taken using a
TECAN plate reader (TECAN Austria GmbH, Salzburg, Austria) and analyzed with
Magellan software. Over 12 replicates were used per treatment group. Hoechst dye
normalized DCF fluorescent units are shown relative to control.
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Protein Expression by Western Blot
Cells were cultured in quadruplicate in 12-well plates (Invitrogen, Carlsbad, CA) in
DMEM/FBS and treated with ca27 for 12 hours at the indicated concentrations. Cells
were washed in cold phosphate buffered saline (PBS) and whole cell extracts were
generated using 1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), 0.1mg/ml phenylmethylsulfonyl fluoride, 1mM sodium orthovanadate, and
10µg/ml aprotinin in PBS. Protein concentrations were determined using the BCA
Protein Assay kit (Pierce Biotechnology, Rockford, IL). 30 µg of protein were sizeseparated by SDS polyacryalmide gel electrophoresis (SDS-PAGE) in triplicate in 12.5%
gels (BioRad, Hercules, CA) and electro-transferred to Immobilon-P membranes
(Millipore Corp., Bedford, MA) using a GENIE wet transfer system (Idea Scientific,
Minneapolis, MN). Membranes were blocked in Trizma base (Tris) buffered saline (TBS)
containing 5% nonfat dry milk at 4°C and then incubated with mouse anti-AR
monoclonal antibody (441; Santa Cruz Biotechnology, Santa Cruz, CA) or mouse anti-βactin monoclonal antibody (A5441; Sigma, St. Louis, MO) at the concentrations
indicated by the manufacturers. After washing in TBS, the membranes were incubated
with a horseradish peroxidase-conjugated goat anti-mouse IgG (Biomeda, Foster City,
CA). Bound antibodies were detected using Western Lightening Chemiluminescence
Reagent Plus (Boston, MA) on a Kodak Image Station 4000MM (Rochester, NY). Band
intensities were determined by densitometric analysis (ratio AR:β-actin) using Kodak
Molecular Imaging Software (Rochester, NY). AR expression is shown relative to
DMSO control.
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Statistical Analysis
Significant differences in values between groups were assessed using the unpaired ttest with SigmaStat 3.1 software (Systat Software, San Jose, CA). P values of less than
0.05 were used to signify statistical significance.

Results
Inhibition of Androgen Receptor Expression by ca27in Human Prostate Cancer
Cells
The effects of the synthetic curcumin analog ca27 (Fig. 1A) were first determined on
the endogenous AR protein expression in different human prostate cancer cell lines, i.e.
LNCaP, C4-2, and LAPC-4. The cells were treated with ca27 for 12 hours at
concentrations in the low micromolar range of 1 to 5μM. Western blot analysis and
densitometric quantitation revealed a significant decrease in AR protein expression in
LNCaP (Fig. 1B), C4-2 (Fig. 1C) and LAPC-4 (Fig. 1D) cells treated with 5 μM ca27.
Five μM ca27 led to a significant reduction of AR protein expression to approximately
30% of control within 12 hours for all the cell lines tested. In addition, there was a
significant decrease in AR protein expression in LAPC-4 (Fig. 1D) cells treated with 1
μM ca27. Curcumin did not down-regulate the AR in our experimental system, as shown
in Figure 1E. C4-2 cells treated with 20 µM ca27 for 72 hours demonstrated a significant
loss of AR protein expression, whereas treatment with up to 20 µM curcumin for 72
hours did not inhibit AR protein expression (Fig. 1E). Similar results were observed in
LNCaP cells (data not shown). To determine whether proteasomal degradation is
involved in AR down-regulation, we used the proteasomal inhibitor MG132. As shown in
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Figure 1F, loss of AR protein expression by ca27 is independent of MG132
administration. LNCaP cells pretreated with 10 µM MG132 for 1 hour and then with 5
µM ca27 for 6 hours showed no inhibition of protein down-regulation in the presence of
the proteasomal inhibitor (Fig. 1F).Collectively, these data indicate that ca27 mediates
the down-regulation of endogenous AR protein in LNCaP, C4-2, and LAPC-4 prostate
cancer cells within 3 hours of treatment independent of proteasomal degradation.
To test whether ca27 affects AR protein levels independent of mRNA transcription,
we used the transcription inhibitor Actinomycin D (Act D). LNCaP cells were treated
with 10 µM Act D or 5 µM ca27 for 3 and 6 hours (Fig. 2). AR protein expression was
significantly inhibited by 5 µM ca27 after 3 hours (Fig. 2A). At this time point, AR
mRNA and protein expression were unaffected by Act D (Fig. 2A and C). However, Act
D significantly inhibited AR mRNA expression after 6 hours (Fig. 2C) but did not inhibit
AR protein expression at this time point (Fig 2B). Together, these data indicate that ca27
at least in part down-regulates AR protein levels independent of its effect on AR mRNA
transcription.

39

40

Fig. 1: Structure of the synthetic curcumin analog ca27 and down-regulation of AR
protein expression by ca27. ca27 (1,5-Bis(2-hydroxyphenyl)-1,4-pentadien-3-one)
consists of two phenolic rings with symmetrical hydroxyl groups on the ortho position of
the aryl rings, which are linked by an unsaturated 5-carbon spacer with a single carbonyl
(A). The synthesis of ca27 was previously described in Weber et al. 2006 (14).Downregulation of endogenous AR protein expression by the synthetic curcumin analog ca27
in LNCaP, C4-2 and LAPC-4 cells. LNCaP (B), C4-2 (C) and LAPC-4 (D) cells were
treated with 1 and 5 μM ca27. AR protein was measured by western blotting and
densitometric analysis (ratio AR:β-actin) after 12 hours. LNCaP (E) cells were treated
with 20 µM ca27 or curcumin for 72 hours AR protein expression was measured and
quantitated as described above. LNCaP (F) cells were pretreated with 10 µM MG132 for
1 hour before the addition of 5 µM ca27 for 6 hours. One representative western blot is
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shown; bars in the graph represent the average of triplicate values + standard deviation.*
denote P< 0.05 compared to control.

Fig. 2: Down-regulation of endogenous AR protein expression by ca27 in LNCaP cells.
LNCaP (A) cells were treated with 10 µM Act D or 5 μM ca27 for 3 hours or 6 hours.AR
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protein (A and B) was measured by western blotting and densitometric analysis (ratio
AR:β-actin) after the indicated time. One representative western blot is shown; bars in the
graph represent the average of quadruplicate values + standard deviation. AR and
GAPDH mRNAs (C) were measured by qRT-PCR. Bars represent the average of
quadruplicate values + standard deviation. AR expression normalized to GAPDH is
shown relative to control. * denote P< 0.05 compared to control.

Inhibition of Cell Growth and Induction of Cell Death by ca27 in Human Prostate
Cancer Cells
The anti-proliferative effects of ca27 were tested on LNCaP and C4-2 prostate cancer
cells. Due to the relatively long doubling time of LNCaP and C4-2 of approximately 48
hours, cell proliferation data was analyzed after 96 hours of treatment. The effect of ca27
on prostate cancer cell growth was determined by cell counts upon treatment with ca27
concentrations between 0.5 μM and 15 μM. As shown in Fig. 3A, ca27 at ≥ 10 μM
markedly inhibited growth of both LNCaP and C4-2 cells. Using trypan blue exclusion,
we also determined the extent of cell death induced by ca27. As shown in Fig. 3B, the
rate of cell death increased extensively and variably at concentrations of > 2.5 µM for
C4-2 cells and > 10 µM for LNCaP cells. These data indicate that the synthetic curcumin
analog ca27 both inhibited prostate cancer cell growth and induced cell death. Of note,
the loss of AR protein expression occurs within a shorter exposure time to ca27 and at
lower concentrations (Figs. 1B and 1C), demonstrating that it precedes the effects on cell
viability. Nevertheless, the loss of AR expression may contribute to cell growth inhibition
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and death, although a pleiotropic effect of ca27 acting through additional pathways
cannot be excluded.

Fig. 3: Growth inhibition and induction of cell death in LNCaP and C4-2 human prostate
cancer cells by ca27. Cell growth (A) and death (B) were determined by total cell counts
and trypan blue positive cell counts, respectively. Cells were cultured in the presence of
0.5, 1, 2.5, 5, 10, or 15 μM ca27 for 96 hours. Bars represent the average of quadruplicate
values + standard deviation. Cell growth and cell viability are expressed as percent of
control.* denote P< 0.05 compared to control.
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Inhibition of Androgen Receptor Activation by ca27 in Human Prostate Cancer
Cells
Other reports demonstrating that curcumin analogs have inhibitory action against the
AR (23-25) prompted us to test the effect of ca27 on AR function. LNCaP and C4-2 cells
(Figs. 4A and 4B) were transiently transfected with a reporter plasmid expressing
luciferase regulated by the MMTV promoter containing androgen responsive elements
(17), cultured in medium containing charcoal stripped serum, and treated for 24 hours
with increasing concentrations of ca27. AR activation measured by luciferase activity
was determined 6 hours after addition of 1 nM R1881 synthetic androgen. As shown in
Fig. 4A, ca27 significantly inhibited AR activation in LNCaP cells at 5 μM. ca27 affected
AR activation similarly in C4-2 cells, with more variation and potentially at lower
concentrations of 2 μM (Fig. 4B).
The ability of ca27 to inhibit AR activation was confirmed using the multifunctional
androgen receptor screening (MARS) assay developed to screen for compounds with
antagonistic and agonistic effects on androgenic activity (19). The MARS assay features
androgen independent PC-3 human prostate cancer cells transiently co-transfected with
an expression vector for the wild-type human AR and a plasmid carrying an androgensensitive promoter regulating the expression of destabilized enhanced GFP (19). In this
sensitive assay, ca27 inhibited AR activation at low micromolar concentrations. In
particular, ca27 above 1 μM proved to be a potent inhibitor of AR activation (Fig. 4C).
Collectively, these data indicate that ca27 is a potent inhibitor of AR activation.

45

Inhibition of Prostate Specific Antigen Expression by ca27in Human Prostate
Cancer Cells
To corroborate ca27 mediated AR down-regulation, we analyzed the effect of ca27 on
the well-established transcriptional target of the AR, prostate specific antigen (PSA).
LNCaP and C4-2 cells were treated with 1 and 5 μM ca27 for 12 hours, followed by
assessment of endogenous PSA mRNA expression by qRT-PCR. In agreement with the
observations on AR, PSA expression was significantly inhibited by 1 μM ca27 at 12
hours (Figs. 4D and 4E). Further, the effect of ca27 on PSA mRNA expression was tested
after 3 hours when AR protein expression was significantly reduced as previously shown
in Figures 1 and 2. At this time point ca27 did not reduce PSA mRNA expression in
LNCaP or LAPC-4 cells (Figs. 4F and 4G). Together, these data indicate that ca27 is able
to rapidly affect a biologically important downstream target of androgenic activity in
prostate cancer cells, i.e. PSA. Further, the lack of PSA inhibition after the short exposure
time of 3 hours suggests that ca27’s effect on PSA is a result of reduced AR activity due
to AR down-regulation.
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Fig. 4: Inhibition of AR activation and endogenous PSA expression by ca27 in LNCaP,
C4-2, and PC-3 cells. (A) and (B): LNCaP (A) and C4-2 (B) cells were co-transfected
with AR reporter plasmid driving firefly luciferase and a thymidine kinase reporter
plasmid driving Renilla luciferase. Cells were treated with ca27 at 2 and 5 μM for 24
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hours. Normalized luciferase activity (relative luciferase units, RLU) was determined 6
hours after addition of 1 nM R1881 synthetic androgen. (C) MARS assay (21): AR- and
dsEGFP-transfected PC-3 cells were treated with increasing concentrations of ca27 for 24
hours and stimulated with 1 nM R1881. Bars in A-C represent the average of
quadruplicate values + standard deviation. AR activation is expressed as percent of
control. (D) and (E): LNCaP (D) and C4-2 (E) cells were treated with 1 and 5 μM ca27.
PSA and GAPDH mRNAs were measured by qRT-PCR after 12 hours. Bars represent
the average of quadruplicate values + standard deviation. PSA expression normalized to
GAPDH is shown relative to control. LNCaP (F) and LAPC-4 (G) cells were treated with
5 µM ca27 for 3 hours. Bars represent the average of triplicate values + standard
deviation. PSA expression normalized to GAPDH is shown relative to vehicle control.*
denote P< 0.05 respectively compared to control.

Increased Cellular Oxidative Stress by ca27 Leads to AR Down-Regulation in
LNCaP Cells
Given the rapid action of ca27,we evaluated the status of oxidative stress upon ca27
treatment in human prostate cancer cells. LNCaP cells were treated for 1 hour with 1-5
µM ca27 and assayed for the production of reactive oxygen species (ROS) as measured
by DCF fluorescence. Treatment of LNCaP cells with 3 µM ca27 led to a significant
production of ROS (Fig. 5A). In order to determine if this significant increase in
oxidative stress by ca27 induces the down-regulation of AR protein expression, LNCaP
(Fig. 5B) and LAPC-4 (Fig. 5C) cells were simultaneously treated with ca27 and the
antioxidant N-acetyl-L-cysteine (NAC) for 3 hours. ca27 (5 µM) significantly inhibited
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AR protein expression after this short incubation time in both cell lines. Further, NAC
prevented ca27 mediated AR protein loss in both LNCaP and LAPC-4 cells. To
determine if the down-regulation of AR protein expression could be due to the inhibition
of AR mRNA by ca27, LNCaP and LAPC-4 cells were treated with 5 µM ca27 for 3
hours and AR mRNA was measured by qRT-PCR. In agreement with our previous result
(Fig. 2C), within this short time period ca27 significantly inhibits AR mRNA expression
in both cell lines (Figs. 5D and 5E). Further, AR mRNA expression is recovered when
cells are simultaneously treated with ca27 and NAC demonstrating that the alleviation of
oxidative stress induced by ca27 prevents the inhibition of AR expression. This result
supports the hypothesis that induction of oxidative stress by ca27 mediates the downregulation of AR expression in human prostate cancer cells.

Activation of Nrf2 and Up-Regulation of Nrf2 Regulated Genes by ca27
A typical downstream effect of cellular oxidative stress is the activation of the critical
cellular redox sensor Nrf2. The increased ROS generation by ca27 treatment led us to
investigate the activation status of Nrf2. A 5 µM ca27 treatment in LNCaP cells
significantly increased Nrf2 activation, as measured by an antioxidant response element
promoter driving a luciferase reporter (Fig. 6A). In addition, in LAPC-4 cells there was a
significant activation of Nrf2 by 1 µM ca27 (Fig. 6B). This result demonstrates that ca27
leads to increased transcriptional activation of Nrf2. In addition, these concentrations are
in agreement with the induction of AR protein down-regulation in the LNCaP and LAPC4 cells as shown in Figs. 1B and 1D. To further illustrate activation of Nrf2 we evaluated
Nrf2 regulated genes such as NQO1, AKR1C1 and MafG. LNCaP cells were treated with
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5 µM ca27 for 3 hours and NQO1, AKR1C1 and MafG mRNA expression was measured
by qRT-PCR. NQO1, AKR1C1 and MafG mRNA expression were increased ≥ 2 fold by
ca27 treatment in comparison to the vehicle control (Fig. 6C). Collectively, these results
corroborate the induction of oxidative stress by ca27 by demonstrating the activation of
Nrf2 and the increased expression of Nrf2 regulated genes.

Fig. 5: Increased ROS generation induced by ca27 and prevention of AR downregulation by antioxidant NAC in LNCaP cells. LNCaP cells were treated with increasing
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concentrations (1, 3, and 5 µM) of ca27 for 1 hour. Increased ROS production was
measured by DCF fluorescence and normalized to DNA content (A). LNCaP (B) and
LAPC-4 (C) cells were treated for 3 hours with or without 5mM NAC in the presence or
absence of 5 µM ca27 and assayed for AR protein expression by western blot; one
representative western blot is shown. Protein expression was quantitated by densitometry.
Bars represent the average of triplicate values + standard deviation. AR expression
normalized to β-actin is shown relative to vehicle control. LNCaP (D) and LAPC-4 (E)
cells were treated for 3 hours with or without 5 mM NAC in the presence or absence of 5
µM ca27 and assayed for AR mRNA expression and normalized to GAPDH bar graph
shown is relative to control.* denote P< 0.05 respectively compared to control. # denote
P< 0.05 respectively compared to ca27 treatment.
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Fig. 6: Nrf2 activation and up-regulation of Nrf2 regulated genes in LNCaP and LAPC-4
cells by ca27. LNCaP (A) and LAPC-4 (B) cells were co-transfected with Nrf2 reporter
plasmid driving luciferase and thymidine kinase reporter plasmid driving Renilla
luciferase. Normalized luciferase activity was determined 16 hours post-treatment with 1
and 5 µM ca27. Bars represent the average of quadruplicate values + standard deviation.
Nrf2 activation is expressed as % of control. LNCaP cells (C) were treated with vehicle
control or 5 μM ca27 for 3 hours. NQO1, AKR1C1 and MafG mRNA expression was
measured by qRT-PCR. Bars represent the average of triplicate values + standard
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deviation. NQO1, AKR1C1 and MafG expression normalized to GAPDH is shown
relative to control. * denote P< 0.05 respectively compared to control.

Discussion
The development of prostate cancer relies initially on androgenic activation of the AR
by testosterone and its more active metabolite dihydrotestosterone (DHT) (1-2). While
AR activation in normal prostatic tissue represents part of normal physiology and
maintains normal differentiation of epithelial cells, in the malignant setting it leads to the
expression of target genes that promote tumorigenesis and cancer progression (11,26).
Clinically, the persistence of AR expression and function in androgen ablation resistant
prostatic tissue is manifested by the successful yet transient application of second line
androgen ablation strategies after primary failure, and by symptoms associated with
androgen withdrawal (27-29). Furthermore, this stage of disease is characterized by a
number of molecular mechanisms supporting the function of the AR in very low or even
absent levels of DHT (10,30-31). Importantly, AR function under these conditions is still
essential for prostate epithelial cell survival, as targeted AR down-regulation in androgen
ablation resistant prostate cancer cell and animal models leads to cell growth inhibition
(8-9). Therefore, given the persisting importance of the AR and its signaling axis in
advanced prostate cancer, it remains a prominent and promising target for this stage of
disease.
The natural product curcumin (diferuloylmethane) has been shown to inhibit many
targets in prostate epithelial cells with an importance in cancer formation and
progression. Among these targets are transcription factors, receptors, intracellular
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kinases, cytokines, and growth factors (32). Curcumin’s effect on the AR and on its target
PSA has been demonstrated by several independent investigators using both
endogenously expressed AR in LNCaP cells and ectopically expressed AR in PC-3 cells
(33-34). However, in these reports curcumin was used at relatively high concentrations,
typically at ≥ 20 μM. It has previously been reported that curcumin has poor
bioavailability which has been determined in both animal models and humans (35). This
limitation has led researchers to generate a variety of synthetic analogs of curcumin and
to investigate their capability to affect a number of molecular pathways implicated in
tumorigenesis and cancer progression (16,36-39). Typical structure modifications include
the introduction of substituents on the biphenyl moieties and modifications of the length
of the linker between the biphenyl rings. A specific group of such analogs has been
exploited towards their ability to inhibit AR function (23-25), and some of these agents
have been shown to down-regulate the expression of AR (24).
Along this line, we report here on the anti-androgenic action of curcumin analog
ca27, which originates from our previously reported chemical libraries (12-14). In
particular, we have shown that ca27 at concentrations below those typically used for
curcumin inhibits the growth of LNCaP and C4-2 human prostate cancer cells. Our data
indicate that the observed growth inhibition and cell death of prostate cancer cells by
ca27 could be in part mediated by the suppression of AR function. In fact, AR protein
expression is significantly down-regulated by ca27 within 3 hours of treatment in various
human prostate cancer cell lines. This rapid loss of AR protein expression could be due in
part to the initial concomitant loss of AR mRNA expression. However, our investigations
using the transcriptional inhibitor actinomycin D at multiple time points indicate an

54

additional post-transcriptional inhibitory effect of ca27 on AR protein. Further, ca27’s
inhibition of the AR is selective, as ca27 significantly inhibited AR but not PSA mRNA
expression in LNCaP and LAPC-4 cells, indicating that PSA inhibition is a result of
reduced AR activity due to AR down-regulation.
ca27 induced AR protein down-regulation seems to be mediated by a distinct
mechanism. We evaluated the actions of a well-established AR degradation mechanism,
the ubiquitin-proteasomal pathway (40-41), and found that ca27 mediated loss of AR
expression was not prevented by the proteasomal inhibitor MG132. This indicates an
alternative down-regulation pathway for the AR activated by ca27. Accordingly, we
show here that a potential mechanism for ca27 mediated AR down-regulation is through
the induction of cellular oxidative stress. We demonstrate the pro-oxidant activity of ca27
by the increased ROS generation in human prostate cancer cells. The induction of ROS
by ca27 was further demonstrated by the transcriptional activation of a known cellular
redox sensor, the transcription factor Nrf2 (42). Further, the expression of Nrf2 regulated
detoxification genes, NQO1 and AKR1C1 (42-43), were significantly increased by ca27.
This is in agreement with a previous study by Dinkova-Kostova et al. who reported that
the identical structure induces NQO1 activity in murine hepatoma and papilloma cells
(44). Further, ca27 induced the mRNA expression of the small Maf protein, MafG. MafG
is a known heterodimerization partner of Nrf2 and leads to Nrf2 transcriptional activity,
and MafG expression has been shown to be regulated by Nrf2 transcriptional activity
under oxidative stress conditions (45). Evidence that AR down-regulation is mediated by
ca27 induced ROS generation is provided by our data showing that AR loss is attenuated
by the addition of the antioxidant NAC. Finally, the generation of cellular oxidative stress
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by ca27 could partially explain the proteasomal-independent down-regulation of the AR
observed in this study, as previous studies have demonstrated that increased cellular
oxidative stress can lead to protein aggregates which inhibit the functions of the
proteasome (46-47). While the exact mechanism(s) of ca27 mediated AR protein downregulation is at present unknown, it seems to entail oxidative stress mediated pathways.
Our results are in agreement with two recent studies showing that AR mRNA
transcription was inhibited in LNCaP and rat hepatoma cells by the pro-oxidant tert-butyl
hydroperoxide (TBH) (48), and that the black seed oil ingredient thymoquinone induces
oxidative stress and affects AR expression (49).

Conclusions
We conclude that the curcumin analog ca27 represents a lead structure with antiandrogenic activity in human prostate cancer cells, possibly through the induction of
oxidative stress. Therefore, ca27 and similar compounds can be exploited as molecular
tools to study pathways relevant to AR protein down-regulation. By extension, given the
prominent role of the AR in prostate cancer (2, 4, 10-11) and because AR degradation has
been recognized as an effective therapeutic strategy (9-10), we propose that ca27 is a
potential lead in the development of novel therapeutics for prostate cancer. This is in
agreement with recent reports on other compounds derived from natural products with
similar anti-androgenic activities mediated by oxidative stress (50), and may represent an
emerging theme for novel prostate cancer therapeutics.
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CHAPTER 3: ALPHA-TOCOPHERYL QUINONE INHIBITS ANDROGEN
RECEPTOR EXPRESSION THROUGH MODULATION OF CELLULAR
REDOX

Abstract
Due to discrepancies in results between epidemiological studies, the role of
tocopherols in cancer prevention is controversial. This may be due, in part, to assuming
equivalency between the biological action of tocopherols and their oxidized forms on
cellular functions. In this study, we show that tocopheryl quinone (TQ), the oxidation
product of vitamin E (VE), has biological properties that are distinct from VE. TQ, but
not VE, was found to have inhibitory activity on both the growth and androgenic activity
of human prostate cells. TQ potently inhibited the growth of androgen-sensitive prostate
cancer cell lines, but did not affect the growth of androgen-independent prostate cancer
cells. Due to the selective growth inhibition observed with androgen-sensitive cells, the
anti-androgenic properties of TQ were examined. TQ treatment led to the significant
down-regulation of androgen receptor (AR) protein expression. Moreover, TQ treatment
inhibited androgen-induced release of prostate specific antigen from androgen-sensitive
prostate cells and the TQ-mediated down-regulation of AR resulted in the inhibition of an
androgen-responsive reporter system. The anti-androgenic action of TQ was further
evidenced by the down-regulation of genes dependent on AR activity for their
expression. Further, we identified a potential mechanism of TQ’s actions on AR downregulation may be in part, due to the increase in oxidative stress as measured by
glutathione levels and the prevention of AR down-regulation in the presence of
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antioxidants. Overall, TQ, but not VE, was shown to be a potent inhibitor of androgenic
activity and AR expression in androgen-sensitive human prostate cancer cells suggesting
that the actions of TQ may account for some of the biological actions attributed to VE.
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Introduction
Prostate cancer is a growing health problem worldwide (1-3), making it an important
candidate for the development of preventive measures (4). The use of vitamin E (VE) for
prostate cancer prevention has become increasingly controversial following the negative
results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (5-7). The
SELECT results contrast those of the alpha-tocopherol, beta-carotene cancer prevention
(ATBC) study, where VE was found to reduce both the incidence and mortality of
prostate cancer (8). A major difference between these two studies is that the participants
of the ATBC trial were all smokers, whereas only a small percentage of participants in
the SELECT were smokers. Other studies support that smoking in combination with VE
supplementation may be responsible for reduced levels of prostate cancer (9-12). An
intriguing explanation for the discrepancies between these studies is that the oxidation
product of VE, tocopheryl quinone (TQ), which may be elevated in the oxidative stress
environment produced by smoking, is the active factor responsible for the decrease in
prostate cancer among smokers taking supplemental VE. To support this hypothesis, VE
and TQ should have differential effects on prostate cancer cells. Indeed, in this study, TQ,
but not VE, was found to have significant anti-androgenic activity. If TQ is active
against prostate cancer development, then men could be supplemented with TQ directly
for more effective prostate cancer prevention.
VE is a family of naturally occurring dietary factors (e.g., -,-,-,-tocopherols and tocotrienols) whose major biologically active form is RRR--tocopherol (13,14). Normal
blood levels of VE are variable with a mean of approximately 25 M (15-17).
Physiologically, VE is believed to act as an antioxidant, reducing cellular oxidative
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damage produced by oxidized lipids (13,14). The major oxidation product of VE as tocopherol is -tocopheryl quinone, which is formed by the two-electron oxidation of the
chromanol moiety of VE (Fig. 1). TQ has unique chemical properties compared to VE.
Although VE has been studied extensively with an interest in reducing disease pathology,
to date, the role of VE in preventing cancer development is unclear. However, VEderivatives are emerging as potentially useful agents to target androgenic activity that
may prove effective for prostate cancer prevention (18,19).
The AR is recognized as a key contributor to prostate cancer development and has
been suggested as a meaningful target for prostate cancer prevention (4). This is
supported by the recognized importance of the AR in prostate cancer progression (20-22)
and from the outcome of studies using inhibitors of testosterone metabolism to prevent
prostate cancer development (21,23,24). The AR is a member of the steroid
hormone/nuclear receptor superfamily (25), which acts as a ligand-activated transcription
factor for genes involved in the growth, survival, and differentiation of the prostate (26).
In addition, AR activity contributes to the development, progression, and maintenance of
prostate cancer (22,27). Down-regulation of AR activation can be achieved either through
direct interference of androgen binding to the AR as with AR antagonists, by decreasing
dihydrotestosterone production with 5-alpha-reductase inhibitors, or by decreasing the
production of testosterone by gonadotropin-releasing hormone agonists (22,27). It should
be noted that these strategies do not directly target the expression of AR protein and thus
the AR remains functional. A unique strategy for prostate cancer prevention is the
identification of agents that down-regulate the expression of AR protein.
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Studies on the actions of TQ are limited compared to the more extensive
investigations on VE. Importantly, to date, no studies addressing the effect of TQ on
prostate cancer cells have been reported. However, down-regulation of AR activity by
VE-related chemicals have been reported. The mechanism of androgenic inhibition by
these agents may be direct or indirect. For example, we have previously shown that the
chromanol moiety of VE blocks androgenic activity by competitive inhibition of
androgen binding to the AR (19). Direct inhibition of the AR has been observed with VE
succinate, which has been shown to down-regulate AR protein in prostate cancer cells in
culture (18). Direct targeting of AR protein may serve as useful strategy for inhibiting the
progression of prostate cancer. In this study, we evaluated TQ’s effects on prostate cancer
cell proliferation, anti-androgenic activity and potential mechanism of AR protein downregulation. Compared to VE, TQ was found to have distinctive properties on androgenresponsive prostate cancer cell lines with notable actions on the expression of the AR.
This study further begins to elucidate the mechanism of TQ’s actions on inhibiting AR
protein expression may be through its activity as a pro-oxidant.

Materials and Methods
dl--tocopheryl quinone was obtained from Research Organics (Cleveland, OH).
Methyltrienolone (i.e., R1881) was obtained from Perkin Elmer/NEN Life Science
Products (Boston, MA). Bicalutamide was from LKT Laboratories, St. Paul, MN.
Vitamin E as dl--tocopherol and other chemicals used in these studies were from Sigma
Chemical Co (St. Louis, MO).
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The LNCaP and DU145 cells used in these studies were acquired from American
Type Culture Collection (Manassas, VA). Cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) containing 5% heat-inactivated fetal
calf serum (FCS; Sigma, St. Louis, MO) with streptomycin-penicillin antibiotics
(designated DMEM/FCS) in a 5% CO2 incubator at 37C. LAPC4 cells adapted to
growth in DMEM and 5% FCS were acquired from Dr. George Wilding (University of
Wisconsin Paul P. Carbone Comprehensive Cancer Center). For most experiments
evaluating androgenic responses, cells were cultured in DMEM containing 4% charcoalstripped FCS and 1% unstripped FCS (designated DMEM/CSS). Methods were
developed to insure that TQ and VE could effectively be delivered to prostate cancer cells
in culture. This was achieved using a carrier-based delivery method for TQ and VE
dissolved first in ethanol which was added to a 7.5% bovine serum albumin (BSA)
solution for a 20-fold concentrated stock. This solution was then added to standard
growth medium at a 5% concentration (i.e., a final concentration of 0.4% BSA) to
produce concentrations of VE in culture medium ranging from 10 to 40 M.
TQ and VE measurements in tissue culture medium
The addition of TQ and VE to medium was performed as described earlier. Levels of
TQ and VE in tissue culture medium were measured using an ESA high-performance
liquid chromatography (HPLC) system (ESA, Inc., Chelmsford, MA) with a 250 mm
AltechLiChrosorb RP-18 reverse-phase column, an ESA model 582 solvent delivery
system, and an ESA CoulArray detector controlled by CoulArray Software for Windows.
The mobile phase consisted of 5 mM sodium acetate and 5 mM acetic acid in HPLC
grade methanol.
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Cell proliferation assays
Relative cell growth changes were determined using DU145, LNCaP, and LAPC4
cells plated in 96-well tissue culture plates. Relative cell numbers with and without TQ
and VE treatment were determined using the CyQUANT NF Cell Proliferation Assay Kit
(Invitrogen), according to kit instructions.
AR protein immunoblot analysis
LNCaP and LAPC4 cells were plated at a density of 1106 cells per 100 mm cell
culture plate in 10 ml of DMEM/CSS and maintained in incubators at 37°C in 5% CO2.
For dose-response studies, LNCaP cells were cultured in 6-well plates (BD Biosciences,
San Jose, CA) in DMEM containing 5% FBS. After a 4 d treatment with vehicle, VE, or
TQ, cells were washed in cold 1 PBS and lysed in a buffer containing 1.0 % Igepal CA630, 0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulfate, 0.1 mg/ml
phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, and 10 µg/ml aprotinin in
1 PBS. Cell extracts were stored at -80°C until analysis. Sample protein levels were
determined using the BCA Protein Assay kit (Pierce Biotechnology, Rockford, IL),
according to kit instructions. Total protein (25 to 30 µg) from cell extracts were
electrophoresed on 12.5 % SDS-polyacrylamide gels (BioRad, Hercules, CA) and
transferred to Immobilon-P membranes (Millipore Corp., Bedford, MA) using a GENIE
wet transfer system (Idea Scientific, Minneapolis, MN). Membranes were blocked in
Tris-buffered saline containing 5% nonfat dry milk at 4°C and then incubated with mouse
anti-AR (441) monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or
mouse anti-β-actin antibody (A5441; Sigma). After washing, membranes were incubated
with a secondary horseradish peroxidase-conjugated goat anti-mouse IgG (Biomeda,
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Foster City, CA) and analyzed using Western Lightening Chemiluminescence Reagent
Plus (Boston, MA) on a Kodak Image Station 4000MM (Rochester, NY). Band
intensities were determined using Kodak Molecular Imaging Software.
Messenger RNA expression analysis
Total RNA was extracted from cells using TRIzol Reagent (Invitrogen) and cDNA
was prepared from total RNA using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA). Quantitative PCR (qPCR) was performed for
mRNA levels using an Applied Biosystems 7900HT Fast Real-Time PCR System
(Carlsbad, CA) and QuantiTect Primers Assays (Qiagen Inc., Valencia, CA) for AR,
NQO1 and GAPDH mRNA. Additional forward and reverse primers used for qPCR are
listed in Table 1.

Table 1: Quantitative PCR primer sequences. 1 Listed from 5 to 3.
Gene

Primer
Primer Sequence1

(Abbreviation)
Prostate Specific
Antigen (PSA)

Direction
Forward

CGCTGGACAGGGGGCAAAA

Reverse

ACAAGTGGGCCCCCAGAATCA

Kallikrein 2 (KLK2) Forward

Prostein (SLC45A3)

CTGGGCTCTGGACAGGTGGTAAA

Reverse

TACAGACAAGTGGACCCCCAGAAT

Forward

CCTCCCTCTACCACCGGGAGAA

Reverse

CCCTCGGTATTTGGGCAGGAA
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Prostatic Acid
Phosphatase (PAP)

NKX3.1 (NKX3-1)

Prostate Specific
Membrane Antigen
(PSMA; FOLH1)

Retinoid X Receptor
alpha (RXR)

Vitamin D Receptor
(VDR)

Aldoketoreductase
1C1 (AKR1C1)

Small MafG (MafG)

X-box protein 1
(XBP-1) Spliced
P58IPK

Activating
transcription factor 4
(ATF4)

Forward

CTTCTTGCCACTTGACGGAATTGT

Reverse

GTGCTGCGTCTCATTCCGGTAGTA

Forward

GGCCGAGACGCTGGCAGAGA

Reverse

GGGCGCCTGAAGTGTTTTCAGAGT

Forward

TCAGTGAGAGACTCCAGGACTTTGA
CA

Reverse

GTTGTGGCTGCTTGGAGCATAGAT

Forward

GTGGAGGCGCTGAGGGAGAA

Reverse

GGCAGGCGGAGCAAGAGCTTA

Forward

CGGGCAGCCACCTGCTCTA

Reverse

TGCGCAGGTCGGCTAGCTTCT

Forward

GATGGCCTAAACAGAAATGTGCGAT

Reverse

GGATAATTAGGGGGGCCAGCA

Forward

GCTGTGCCCCCGGGTTATGA

Reverse

CCGTCAGGCTGGTGCCATTCT

Forward

CCGCAGCAGGTGCAGG

Reverse

GAGTCAATACCGCCAGAATCCA

Forward

GAGGTTTGTGTTGGGATGCAG

Reverse

GCTCTTCAGCTGACTCAATCA

Forward

TAGGGGCCTCCTACCTTTGT

Reverse

GTGTCATCCAACGTGGTCAG
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Activating
transcription factor 6
(ATF6)

CHOP

Forward

GCCTTTATTGCTTCCAGCAG

Reverse

TGAGACAGCAAAACCGTCTG

Forward

ATGGCAGCTGAGTCATTGCCTTTC

Reverse

AGAAGCAGGGTCAAGAGTGGTGAA

Prostate specific antigen analysis
LNCaP cells were cultured in 96-well plates at 5x103 cells per well in DMEM/CSS 1
d before treatment. After a 4 d treatment with 50 pM R1881 and TQ or VE, media levels
of PSA released from LNCaP cells were measured using a PSA Enzyme Immunoassay
Test Kit (BioCheck, Inc., Foster City, CA) according to the kit’s instructions. PSA levels
were normalized to cell number, which were determined using the CyQUANT NF Cell
Proliferation Assay Kit (Invitrogen) described above.
Promoter activation assay
LNCaP cells were cultured in 12- or 24-well plates (Invitrogen) in DMEM/CSS 2 to 3
d before transfection. Androgen-induced transcriptional activation was determined using
a reporter construct with an androgen-sensitive MMTV-LTR that regulates the expression
of luciferase (25,28). Cells were transfected using the calcium phosphate precipitation
method with the MMTV/luciferase plasmid (28). Twenty-four h after transfection, cells
were treated with R1881 with or without test reagents at the specified concentrations.
Cell extracts were acquired after treatment in 100 L of Cell Culture Lysis Reagent
(Promega, Madison, WI). Luciferase activity was measured using the Luciferase Assay
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Substrate (Promega) and relative luciferase units determined on a TD-20/20
Luminometer (Turner Designs, Sunnyvale, CA).
Glutathione Assay
LNCaP cells were cultured in 6-well plates in DMEM containing 5% FBS. LNCaP
cells were treated for the indicated times and total cell number was determined by a
hemacytometer and light microscopy immediately after collection. GSH and GSSG were
measured using a modified Tietze et al. (29) protocol of the GSH/GSSG Ratio Assay Kit
(Calbiochem, San Diego, CA) in combination with 2-vinyl pyridine and triethanolamine
according to instructions from Rhaman et al. (30). GSHt and GSSG were determined
according to the kit’s instructions. GSHt and GSSG were normalized to total cell number.
Statistical analysis
Significant differences in values between groups were assessed using an unpaired ttest with SigmaStat 3.1 software (Systat Software, Inc., San Jose, CA). P values less than
0.05 were used to signify statistical significance. Studies were performed as specified
with a minimum of 3 samples (i.e., n 3).

Results
Validation of TQ and VE dissolution in tissue culture medium
TQ and VE are composed of lipophilic hydrocarbon chains (Fig. 1) that greatly limit
their solubility in cell culture medium and, thus, complicates the treatment of cells in
culture with these agents. Therefore, for these studies, methods were developed to
effectively treat prostate cancer cells in culture with TQ and VE. This was achieved using
bovine serum albumin (BSA) as a carrier-based delivery method. BSA was found to be
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suitable carrier for the administration of TQ and VE at levels up 40 M. Validation of TQ
and VE dissolved in medium were performed using HPLC and electrochemical detection
(see Materials and Methods). Fig. 2A and Fig. 2B show electrochemical detector output
from an HPLC analysis for VE and TQ, respectively. Fig. 2C shows that increasing
concentrations of VE in cell culture medium were linear from 1 to 40 M, which was
found to be similar for TQ (data not shown). Because normal blood levels of VE range
from 20 to 30 M (15-17), for most experiments performed in this study, a concentration
of 25 M TQ and VE was used, unless specified otherwise.

Fig. 1: Tocopherylquinone is produced by the two-electron oxidation of the chromanol
moiety of vitamin E (VE).
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Fig. 2: Analysis of VE and TQ. Retention time determination of VE (A) and TQ (B)
analyzed by HPLC using electrochemical detection. The sensitivity of detection was
greatest with an array potential of +500 mV for both VE and TQ (A & B; arrows). (C) A
linear relationship of VE in cell culture media was observed for the concentration range
tested of 0 to 40 µM.
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Inhibition of prostate cancer cell growth by TQ
Previous studies have demonstrated that ester-conjugated, water soluble VE analogs
(e.g., vitamin E succinate) can inhibit prostate cancer cell growth in culture (18,31).
Using the methods described in this study to dissolve the free forms of TQ and VE, their
ability to inhibit prostate cell growth was determined. TQ treatment inhibited cell
proliferation of AR expressing LAPC4 cells but had minimal effect on the androgenindependent DU145 prostate cancer cell line, which does not express the AR, after
treatment with concentrations of up to 40 M TQ (Fig. 3A). In contrast, treatment with
TQ produced a dose-dependent decrease in prostate cancer cell growth in LAPC4 (Fig.
3B) and LNCaP (Fig. 3C) androgen-sensitive prostate cancer cells, which was
significantly reduced at a low dose of 10 M TQ. A small, but significant, decrease in
LAPC4 cell growth was observed at VE treatment levels equal to or greater than 30 M
(Fig. 3B). In LNCaP cells, treatment with VE up to 40 M did not significantly decrease
growth (Fig. 3C).

77

Fig. 3: TQ inhibits prostate cancer cell proliferation in androgen-sensitive prostate cancer
cell lines. (A) Comparison of growth changes induced by TQ treatment in androgensensitive LAPC4 cells and androgen-independent DU145 prostate cancer cells treated
with 10 to 40 M TQ. (B) The growth of LAPC4 cells treated with either TQ or VE for 4
d, which was significantly decreased after treatment with 10 to 40 M TQ and  30 M
VE (*P<0.05). (C) Determination of LNCaP cell growth after treatment with either TQ or
VE for 4 d. Cell growth was significantly decreased after treatment with 10 to 40 M TQ
(*P<0.05). In contrast, cell growth in LNCaP cells was not altered by 10 to 40 M VE
treatment.
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Down-regulation of AR protein levels in androgen-responsive prostate cancer cells
by TQ
To determine the effects of TQ on AR protein in androgen-responsive LNCaP and
LAPC4 cells, immunoblots for AR protein were performed. For each immunoblot, AR
protein levels were normalized to levels of β–actin protein, which was not affected by
TQ. The levels of AR protein were measured in LNCaP cells treated with 4, 12.5, or 25
µM TQ for 4 d in LNCaP cells. Cells treated with TQ showed significantly reduced AR
protein levels (Fig 4 A-B). Similar to LNCaP cells, TQ significantly inhibited AR protein
levels in LAPC4 cells (Fig. 4 C-D). LAPC4 cells were treated with TQ for 24, 48, 72, and
96 h (Fig. 4D). Twenty-four h treatment with 25 µM TQ significantly inhibited AR
protein expression with a time-dependent decrease in AR protein levels up to 96 h (Fig.
4D). Therefore, TQ produced a dose- and time-dependent down-regulation of the AR
protein in androgen-sensitive prostate cancer cell lines.
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Fig. 4: AR protein levels determined by immunoblot in androgen-sensitive prostate
cancer cells treated with TQ and VE. Quantified AR protein levels are present below
each blot. (A) Immunoblot analysis of AR protein expression in LNCaP cells treated for
4 d with 25 µM TQ or 25 µM VE compared to vehicle control treated cells. Treatment
with 25 µM TQ significantly reduced AR protein expression in comparison to control
cells (*P<0.05). (B) AR protein expression in LAPC4 cells treated with 25 µM TQ or 25
µM VE for 4 d. TQ significantly reduced AR protein expression (*P<0.05). (C) TQ dosedependent reduction in AR levels in LNCaP cells treated with 4, 12.5, or 25 µM TQ for 4
d. (D) Representative immunoblot of time-dependent changes in AR protein levels from
LAPC4 cells treated with 25 µM TQ. AR protein levels were significantly reduced after
24 h in LAPC4 cells, which remained decreased for up to 96 h (*P<0.05). For all
immunoblots, quantification of AR protein levels was normalized to β-actin.
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The androgenic response of LNCaP cells is decreased by TQ treatment
Studies to determine if TQ or VE modulated AR activity were initiated using an
androgen-sensitive luciferase reporter system. For this study, androgen-sensitive reporter
activity was stimulated using the synthetic androgen R1881 and was assessed after
treatment with either 30 M TQ or VE (Fig. 5A). TQ treatment alone did not modulate
reporter activity. In contrast, TQ was found to significantly inhibit R1881-induced
reporter activation after 2 d in comparison to R1881-stimulated control cells.
Surprisingly, 30 M VE treatment increased androgen-sensitive reporter activity (Fig.
5A). This data supports an inhibitory role for TQ on AR activity in contrast to VE, which
did not exhibit antiandrogenic activity.
The release of prostate specific antigen (PSA) from LNCaP cells is recognized as a
sensitive indicator of androgenic response in LNCaP cells (32). To further examine TQ’s
effects on androgenic pathways, the androgen-stimulated release of PSA from LNCaP
cells was determined. LNCaP cells treated with TQ showed a dose-dependent reduction
in R1881-induced PSA release compared to untreated control cells (Fig. 5B). In contrast,
treatment with 10 to 40 M VE did not affect androgen-induced PSA release from
LNCaP cells (Fig. 5B).
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Fig. 5: Inhibition of androgenic responses in LNCaP cells by TQ treatment. (A)
Androgen-induced (i.e., R1881 (R)) luciferase expression from an androgen-sensitive
promoter measured after TQ or VE treatment for 48 h. VE treatment, but not TQ,
increased promoter activity compared to control, untreated LNCaP cells (*P<0.05). In
LNCaP cells stimulated with 50 pM R1881 and the established antiandrogen
bicalutamide (Bical) or TQ showed decreased promoter activity compared to cells
stimulated by exposure to 50 pM R1881 alone (# P<0.05). (B) PSA release was
stimulated by 50 pM R1881 exposure in LNCaP cells and measured 4 d after TQ or VE
treatment. PSA levels were significantly lower from cells treated with 10 or 40 M TQ (*
P<0.05), but remained unchanged by VE treatment.

TQ, not VE, treatment decreases AR and AR responsive gene mRNA levels
The decrease in PSA release may be due in part to down-regulation of PSA gene
expression by TQ (Table 2). In addition to PSA mRNA levels, other androgen-responsive
genes were measured after TQ treatment. As shown in Table 2, the mRNA levels for the
AR responsive genes kallikrein 2, prostein, prostatic acid phosphatase, NKX3.1 and
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prostate specific membrane antigen were reduced in LNCaP cells 4 d after treatment with
TQ. In contrast to TQ, VE treatment did not decrease expression of the androgensensitive mRNAs (Table 2).
To determine the effects of TQ and VE on AR protein in androgen-responsive
LNCaP and LAPC4 cells, immunoblots for AR protein were performed. For each
immunoblot, AR protein levels were normalized to levels of β–actin protein, which was
not affected by TQ or VE. LNCaP cells treated with TQ showed significantly reduced
AR protein levels; whereas VE did not change AR protein levels (Fig. 6A). Similar to
LNCaP cells, TQ significantly inhibited AR protein levels in LAPC4 cells and VE did
not affect the levels of AR protein (Fig. 6B) after 96 h. We further demonstrate TQ
down-regulates AR mRNA and this action is distinct from VE, the levels of AR mRNA
were measured using qPCR after treatment with 25 µM TQ or VE for 96 h. AR mRNA
levels were decreased 1.4- and 1.7-fold after treatment with 25 M TQ in LNCaP and
LAPC4 cells, respectively (Fig. 6C-D). However, mRNA down-regulation was not an
overt action of TQ in prostate cancer cells as neither retinoid X receptor, alpha mRNA
nor vitamin D receptor mRNA levels were decreased (Fig. 6E-F). It is interesting to note
that whereas VE treatment did not affect the mRNA levels of androgen-responsive genes,
the AR, or the vitamin D receptor, VE produced a 20% reduction in retinoid X receptor,
alpha mRNA levels.
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Table 2: Down-regulation of androgen-responsive gene expression in LNCaP cells by
TQ.

Gene

Fold decrease in
(mRNA)1, 2

Gene Symbol

TQ

VE

Prostate Specific Antigen (PSA)

KLK3

9.1

1.1

Kallikrein 2

KLK2

7.1

1.0

SLC45A3

2.6

1.2

ACPP

2.4

1.2

NKX3.1

NKX3-1

1.9

1.1

Prostate Specific Membrane
Antigen (PSMA)

FOLH1

1.5

1.1

Prostein
Prostatic Acid Phosphatase (PAP)

1

Determined using quantitative PCR (see Materials and Methods).

2

Compared to control, vehicle-treated LNCaP cells.
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Fig. 6: VE does not alter AR protein or mRNA levels in AR-expressing prostate cancer
cells. (A) Immunoblot analysis of AR protein expression in LNCaP cells treated for 4
days with 25 µM TQ or 25 µM VE compared to vehicle control treated cells. (B) AR
protein expression in LAPC4 cells treated with 25 µM TQ for 4 days. (C) Quantitative
PCR analysis of AR mRNA levels in LNCaP cells treated for 4 days with 25 µM TQ or
25 µM VE compared to vehicle control treated cells. (D) AR mRNA levels in LAPC4
cells treated for 4 days with 25 µM TQ or 25 µM VE. TQ does not inhibit RXR or VDR
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mRNA expression levels. Levels of RXR mRNA (E) and VDR mRNA (F) in LNCaP
cells treated for 4 days with 25 µM TQ or 25 µM VE. RXR or VDR mRNA expression
levels were not changed in LNCaP cells treated with 25 µM TQ (* P<0.05).

AR protein down-regulation by TQ is selective, independent from proteasomal
degradation and independent of mRNA expression
To determine the relative selectivity of TQ’s actions on the AR we evaluated the
expression of the ligand activated basic helix-loop-helix transcription factor the aryl
hydrocarbon receptor (AHR). TQ significantly inhibits AR protein expression, but not
AHR protein expression in LNCaP cells after 48h of 25µM treatment (Fig. 7A-C). As
shown in Fig. 7A-C TQ significantly inhibited AR protein expression and in contrast
significantly increased AHR protein expression.
Degradation of the AR is primarily mediated through the activity of the ubiquitinproteasome pathway. To determine if TQ increased AR proteasomal degradation LNCaP
cells were treated with 10µM of the proteasomal inhibitor MG132 in the presence or
absence of TQ. TQ’s down-regulation of the AR was not attenuated by the presence of
MG132 (Fig. 7D-E). Investigators used multiple concentrations of MG132 and various
treatment strategies but the results were consistent in that inhibition of proteasomal
degradation did not prevent AR down-regulation by TQ.
The down-regulation of AR protein by TQ may be mediated through the inhibition of
AR mRNA. To address this potential mechanism a time course experiment was
conducted in which protein and mRNA extracts were collected from the same treatment
sample. Although there was a significant inhibition of AR mRNA at 96 h upon TQ
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treatment, as shown previously in Fig. 6C, this inhibition was not correlated with the
down-regulation of AR protein expression (Fig. 7 F-H). In contrast to the significant
down-regulation of AR mRNA at 96h by TQ, AR protein was significantly inhibited by
48h in these matched samples.
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Fig. 7: Selective down-regulation of AR protein expression by TQ in LNCaP cells. (A)
Immunoblot analysis of AHR and AR protein expression in LNCaP cells treated for 48 h
with 25 µM TQ compared to vehicle control treated cells. (B) Immunoblot analysis of
AHR protein expression or (C) AR protein expression after TQ treatment. (D) LNCaP
cells were treated with 25 μM TQ for 16 h and then treated with 10μM MG132 for an
additional 24 h (D+E) (*P<0.05 compared to control). (F) Quantitative PCR analysis of
AR mRNA levels and (G+H) immunoblot analysis of AR protein expression in LNCaP
cells treated for 1-4 d with 25 µM TQ (*P<0.05 compared to control).

TQ induces cellular oxidative stress
To determine TQ’s cellular mechanism of action we measured total glutathione
(GSHt) and oxidized glutathione (GSSG) levels after 96h of treatment (Fig. 8A-B).
To determine if TQ’s down-regulation of the AR was potentiated by the depletion of
GSH levels, LNCaP cells were treated with TQ and the glutathione ligase (gamma-
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glutamylcysteine synthetase) inhibitor buthionine sulfoximine (BSO). TQ significantly
inhibited AR protein expression and this inhibition was significantly potentiated by the
presence of BSO (Fig. 8C-D). In order to confirm if the observed increase in oxidized
glutathione levels was due to increased oxidative stress, we evaluated genes regulated by
the antioxidant response element (ARE). The ARE is activated upon binding of the
cellular redox sensor nuclear factor E2-related protein 2 (Nrf2) and regulated the
expression of genes such as, Nadph quinone oxidoreductase 1 (NQO1), aldoketoreductase
1C1 (AKR1C) and MafG. NQO1, AKR1C1 and MafG mRNA expression were
significantly increased upon 25µM TQ treatment after 96h (Fig. 8E).
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Fig. 8: TQ modifies glutathione expression and inhibition of glutathione production
potentiates TQ’s down-regulation of AR protein expression. (A) Expression of total
glutathione and (B) oxidized glutathione were measured after treatment with 25 µM TQ
or vehicle control for 96 h in LNCaP cells. (C+D) Immunoblot analysis of AR protein
expression in LNCaP cells. Cells were pretreated with 5mM BSO for 24 h and then
treated with 25 µM TQ or vehicle control in the presence or absence of BSO for an
additional 48 h. (E) Quantitative PCR analysis of NQO1, AKR1C1 and Maf G mRNA
levels in LNCaP cells treated for 96 h with 25 µM TQ (*P<0.05 compared to control).
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Fig. 9: TQ increases expression of UPR regulated transcripts and activation of UPR by
tunicamycin leads to AR down-regulation. (A) Quantitative PCR analysis of XBP-1
(spliced), P58IPK, ATF4 and ATF6 mRNA levels in LNCaP cells treated for 96 h with 25
µM TQ. CHOP mRNA levels were measured after 25 µM TQ treatment for 48 h. (B+C)
Immunoblot analysis of AR protein expression in LNCaP cells. Cells were treated with
2ug/ml tunicamycin (TM) for 24 h or 48 h (*P<0.05 compared to control).

TQ activates the Unfolded Protein Response and activation of UPR leads to AR
down-regulation
With the induction of oxidative stress by TQ treatment and the selective inhibition of
AR protein expression investigators addressed if this agent led to activation of the
Unfolded Protein Response (UPR). There are three key signaling pathways that are
activated in the UPR, PERK, IRE1 and ATF6. Down-stream genes that are increased
upon activation of these pathways such as, ATF4, XBP-1 spliced, ATF6 and CHOP were
significantly increased upon TQ treatment. LNCaP cells were treated with 25µM TQ for
96h, the transcripts XBP-1 spliced and ATF6 were increased 5-fold. There was a small
but significant increase in ATF4 mRNA expression 1.7-fold and a 6-fold increase in
CHOP in as early as 48 h (Fig. 9A). To further determine if activation of the UPR by the
inducer tunicamycin led to the down-regulation of AR protein expression LNCaP cells
were treated with 2 µg/ml for 24 and 48 h. There was a significant inhibition of AR
protein expression upon tunicamycin treatment at both 24 and 48h (Fig 9B-C).
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Fig. 10: Inhibition of AR protein expression by TQ is attenuated by antioxidants NAC
and VE. (A) Immunoblot analysis of AR protein expression in LNCaP cells pretreated for
24 h with 5 mM NAC and then treated with 25 µM TQ in the presence or absence of 5
mM NAC for 48 h. (B) Immunoblot analysis of AR protein expression in LNCaP cells
pretreated for 24 h with 25 µM VE and then treated with 25 µM TQ in the presence or
absence of 25 µM VE for an additional 48 h (*P<0.05 compared to control).

TQ’s down-regulation of AR expression is attenuated by the presence antioxidants
NAC and VE
The antioxidants N-acetylcysteine (NAC) and Vitamin E (VE) were used to
determine if a potential mechanism of TQ’s down-regulation of AR protein expression is
through the increase in oxidative stress (Fig 10 A-D). LNCaP cells were pre-treated with
5mM NAC or 25µM VE for 24h and then treated with 25µM TQ with or without NAC
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(Fig 10 A-B) and VE (Fig. 10 C-D) for 48h. TQ’s down-regulation of AR protein
expression was significantly attenuated by the presence of either antioxidant.

Discussion
Biological actions for TQ, the oxidation product of VE, are largely undefined. Here,
we begin to identify TQ’s anti-androgenic activity is through its actions as a potential
pro-oxidant. VE did not significantly affect either the growth of prostate cancer cells or
pathways known to be critical in prostate cancer progression compared to TQ. TQ
significantly inhibited AR protein expression, activated antioxidant pathways and
induced ER stress pathways. This study begins to identify a novel activity of TQ (α-TQ)
as a potential arylating electrophile in human CaP cells. This potential activity is in
contrast to previous studies reporting the weak electrophile activity of α-TQ in
comparison to γ- or δ-TQ. In addition, we do not observe overt toxicity in the cell lines
tested upon TQ treatment. However, in the studies evaluating the activity of TQ (α-TQ)
versus γ- or δ-TQ were conducted within a relative short time period, we observe a timedependent activity of TQ within our system (33). For example, TQ’s down-regulation of
AR protein expression in LNCaP cells requires 48 h for significant inhibition as does its
pro-oxidant activity. We further demonstrate TQ’s down-regulation of the AR is
attenuated by the antioxidants VE and N-acetylcysteine (NAC). TQ’s anti-androgenic
actions in prostate cancer cells may be an explanation for the chemopreventive actions of
VE in men who smoke (ATBC trial) (10) and the lack of prevention in men who are nonsmokers (SELECT trial) (7).
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In this study VE did not significantly affect either the growth of prostate cancer cells
or pathways known to be critical in prostate cancer progression compared to TQ, which
potently inhibited the growth of androgen-sensitive prostate cancer cells. The decrease in
cell growth produced by TQ treatment may be AR-dependent as TQ treatment did not
have a pronounced effect on the growth of the androgen-independent DU145 human
prostate cancer cell line. Importantly, TQ, but not VE, was found to reduce both AR
mRNA and AR protein levels in prostate cancer cells with a concomitant reduction in
androgenic pathways. Several studies have shown that down-regulation of the AR results
in decreased cell proliferation in androgen-sensitive prostate cancer cells. For example,
decreased AR expression was achieved in LNCaP human prostate cancer cells using
siRNA resulting in a decrease in LNCaP growth (34,35). Thus, the decrease in cell
growth produced by TQ in androgen-sensitive prostate cancer cell lines may be due at
least in part to the action of TQ to down-regulate AR expression.
The AR is a tissue-specific, ligand-activated transcription factor that is known to
regulate the expression of genes such as PSA, kallikrein 2, prostein, prostatic acid
phosphatase, NKX3.1, and prostate specific membrane antigen in prostate cells (36-40).
Because the AR plays a key role in maintenance of the expression of these genes, the
reduced expression of these genes would result from down-regulation of the AR. In fact,
the expression of several of these genes was reduced after treatment of LNCaP cells with
TQ. Additionally, expression from an androgen-sensitive reporter was inhibited by
concurrent androgen and TQ treatment. In contrast, VE had minimal effects on the
modulation of androgen-responsive genes or gene products. The reduced expression of

96

AR-responsive genes induced by TQ treatment strongly supports that the AR is a major
target of TQ in prostate cancer cells.
The AR is recognized as a major contributor to all stages of prostate cancer from
carcinogenesis to castration-resistant disease (22,27,41,42). To date, most interventions
against prostate cancer reduce AR activation through inhibiting the production of
androgenic ligands, such as testosterone or dihydrotestosterone. These strategies do not
affect the AR itself. To modulate AR activity, it is necessary to identify interventions that
target down-regulation of AR expression in prostate cells. Here, we show that downregulation of AR protein and mRNA can be achieved using TQ, the natural oxidation
product of VE, with a pronounced impact on androgenic activity in prostate cancer cells.
It is noteworthy that VE as -tocopherol did not inhibit either AR expression or activity
in prostate cancer cells. This is important as this is the form of VE that is expected to be
physiologically active in contrast to ester conjugated forms, such as vitamin E succinate,
that are converted -tocopherol by esterases in the body. Although VE did not exhibit
anti-androgenic properties within our system VE analogs have been reported to affect AR
protein expression in prostate cancer cells. For example, Zhang et al. (31) reported that
the VE analog, VE succinate, reduces AR activity in androgen-sensitive human prostate
cancer cells. Similar to TQ, VE succinate treatment was found to decrease both AR
mRNA and protein levels in LNCaP cells (31). Importantly, Zhang et al. (31) found that
at least part of VE succinate’s action is due to a decrease in AR translation. We have
previously reported on the anti-androgenic activity of another VE analog, 2,2,5,7,8Penatmethyl-6-chromonol (PMCol) (19). This antioxidant moiety of VE, PMCol, consists
of the chromonal ring structure of VE but lacks the phytyl chain. Thompson et al. (19)

97

demonstrated PMCol inhibited androgen sensitive prostate cancer cells proliferation, acts
as a competitive inhibitor of AR ligand binding and inhibits AR activation. However,
PMCol did not inhibit AR expression within in these cells. Identifying the mechanism of
TQ’s anti-androgenic activity and selective inhibition of AR protein expression may
provide insight into novel AR regulatory mechanisms.
Because TQ had pronounced inhibitory effect on markers of AR activity, the AR in
androgen-sensitive prostate cancer cell lines was examined. Both AR protein and AR
mRNA were found to be reduced by TQ treatment. However there was significant
reduction of AR protein expression that preceded the inhibition of AR mRNA expression.
Demonstrating TQ’s actions on AR down-regulation may not be entirely due to the
inhibition of AR mRNA expression. To determine the relative selectivity of TQ’s actions
on AR protein expression we evaluated the expression of the aryl hydrocarbon receptor.
TQ significantly induced AHR protein expression within 48 h. Further, we demonstrate
the increase of several different transcripts such as VDR, RXRα, NQO1, AKR1C1 and
CHOP in comparison to the significant inhibition of AR mRNA expression. We also
demonstrate that TQ’s down-regulation of AR protein expression in not mediated through
proteasomal degradation. To determine the mechanism(s) of action involved in TQmediated down-regulation of AR expression in CaP cells we examined TQ’s potential
actions as a pro-oxidant. TQ was found to increase the levels of total glutathione and
oxidized glutathione (GSSG). Glutathione is a major antioxidant redox recycling thiol
which plays a major role in cellular defense against oxidative insult (43). GSH and GSSG
balance has been reported to be critical regulator in maintaining the proper folding and
function of various proteins. Perturbations of the GSH/GSSG ratio within the lumen of
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the ER can interfere with the activity of protein disulfide isomerases (PDI) which can
directly lead to protein misfolding (44). Accumulation of these misfolded proteins within
the lumen of the ER leads to ER stress and the activation of the unfolded protein response
(UPR). The UPR is mediated through the activation of three ER stress pathways
pancreatic ER kinase (PKR)-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1)
and activating transcription factor 6 (ATF6) (45). We demonstrate the up-regulation of
known target genes of the PERK, IRE1 and ATF6 pathways. ATF4, p58IPK, XBP-1
spliced, ATF6 and CHOP mRNA expression are significantly increased upon treatment
with TQ.
CHOP is a known death mediator whose expression is increased by all three UPR
signaling cascades and although TQ is not overtly toxic by 96 h, longer time points have
not been evaluated (46). Further, we demonstrate treatment of LNCaP cells with a known
inducer of ER stress tunicamycin, significantly inhibits AR protein expression by 24 h.
Tunicamycin is an inhibitor of N-glycosylation which leads to the accumulation of
misfolded proteins within the lumen of the ER inducing ER stress and activation of the
UPR (47). The UPR activation observed by TQ treatment occurs at later time points than
that observed for AR protein down-regulation thus it may not explain the early activity of
TQ but provides insight into the mechanism of TQ’s actions.
Reports on the biological effects of TQ are limited. This may be due in part to TQ
being regarded simply as the product of VE oxidation with limited inherent biological
activity. However, TQ is chemically distinct from VE and, therefore, may have unique
biological actions compared to VE. The distinct biological actions of TQ and VE are
strongly supported by the results on selective AR down-regulation by TQ observed in the
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current study. A physiological action associated with TQ is anticoagulant activity (48).
This is not surprising in that the quinone and phytyl chain structure of TQ is reminiscent
of vitamin K, a critical vitamin involved in blood clotting. In general, chemicals
possessing quinone structures are found to be toxic. This is largely due to the presence of
electrophilic carbon centers present in the quinone structure that may be acted upon by
nucleophiles present in cellular constituents. In the current study, TQ was not found to be
highly cytotoxic. Interestingly, all electrophilic sites in TQ are blocked by methyl
substitutions and thus TQ would be expected to be less reactive than chemicals with
unblocked quinone structures. Additionally, TQ has been found to be a potent substrate
for the biotransformation enzyme NAD(P)H quinone oxidoreductase 1 (NQO1) (49). The
reduction of TQ to the hydroquinone by NQO1 was found to be so efficient it was
suggested that TQ may be one of the primary substrates for NQO1’s biological activity
(49). Results from the current study and others strongly support that TQ has potent
biological actions that are distinct from VE.
The actions of VE as a measure for alleviating prostate cancer are controversial.
Intriguingly, some epidemiological studies support a role for the prostate cancer
preventive actions of supplemental VE when taken by men who smoke, an activity that
produces a chronic physiologic oxidative stress. For example, the Finnish -Tocopherol,
-Carotene Cancer Prevention Study examined men that were heavy smokers (8). In this
study, a 32% reduction in prostate cancer incidence and 41% reduction in mortality was
observed among smokers taking supplemental VE compared to control groups (8). In the
Harvard Health Professionals study, no effect of supplemental VE alone was found on
prostate cancer incidence; however it was reported that, “among current smokers and
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recent quitters, those who consumed at least 100 IU of supplemental VE per day had a
relative risk of 0.44 for metastatic or fatal prostate cancer” (9). Two additional studies
have found no effect of supplemental VE when taken alone, but did report a reduction in
the development of prostate cancers among smokers taking VE supplements (10,11). In
contrast to these reports, a recent study has found that VE itself may have activity against
the development of advanced prostate cancer (50). This finding conflicts with the results
from the Selenium and Vitamin E Cancer Prevention Trial (i.e., SELECT), which failed
to find prostate cancer preventive actions of supplemental VE (6,7). Thus, most studies to
date suggest that VE itself may not be an effective intervention against prostate cancer. In
agreement with these findings, the results from the current study did not find significant
effects on prostate cancer cells by VE. However, we have found that TQ, the major
oxidation product of VE, is highly effective at reducing both growth and androgenic
activity in prostate cancer cell lines. It is intriguing to consider that TQ may be the active
derivative of VE involved in prostate cancer prevention among heavy smokers taking
supplemental VE, which in possessing a physiologic oxidative stress effectively
transforms VE to TQ. The results from the current study strongly support further
investigations to determine the efficacy of TQ as a modality for prostate cancer
prevention.
In conclusion, we have begun to identify TQ’s mechanism of action as a potential
pro-oxidant which induces oxidative stress, activation of the UPR and down-regulates
AR protein expression in human prostate cancer cells. TQ’s down-regulation of AR
protein expression was attenuated by the presence of the antioxidants NAC and VE. This
study provides insight into how the actions of TQ may be an explanation for the
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discrepancies found in various chemopreventive trials using VE. Further investigation
into TQ’s actions can provide insight into novel mechanisms of AR down-regulation as a
potential prostate cancer chemopreventive strategy.
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CHAPTER 4: ACTIVATION OF THE ARYL HYDROCARBON RECEPTOR BY
ALPHA-TOCOPHERYLQUINONE AND CURCUMIN ANALOG 27 AND
EFFECTS ON THE ANDROGEN RECEPTOR

Abstract
The AHR is a ligand activated transcription factor that regulates the expression of
several genes involved in Phase I and II metabolism. The oxidative metabolite of vitamin
E, alpha-tocopheryl quinone (TQ) and the curcumin analog 27 (ca27) have significant
anti-androgenic effects and down-regulate AR protein expression in human prostate
cancer (CaP) cells. In this study, both TQ and ca27 are shown to induce AHR activation
and increase the expression of AHR regulated transcript CYP1A1 in CaP cells. However,
the effects on AHR expression are different between TQ and ca27. ca27 significantly
down-regulates AHR protein expression. In contrast, TQ increased AHR mRNA and
protein expression in a time-dependent manner. In examining these agents’ mechanism(s)
of AHR regulation interactions of AHR and AR in CaP cells were evaluated. TQ and
ca27 down-regulate AR protein expression in a dose- and time-dependent manner. The
mechanism of AR protein down-regulation by TQ or ca27 was independent of the AHR.
However, TQ modulated AHR expression and activity. TQ was shown to induce
CYP1A1 expression through an AHR dependent-mechanism. This is the first study
demonstrating TQ’s activity as an AHR agonist in human CaP cells. Differential effects
on AHR expression by TQ and ca27 were observed providing a potential role for the
AHR toward these agents’ mechanism(s) of AR down-regulation.

111

Introduction
The aryl hydrocarbon receptor (AHR) is a member of the basic helix-loop-helix
(bHLH-PAS) transcription factors which include Period (Per), AHR nuclear translocator
(ARNT) and single minded (SIM) (1). The AHR is a ligand activated transcription factor
which heterodimerizes with ARNT to activate gene transcription through a xenobiotic
(dioxin) response element (XRE or DRE). Over 400 environmental toxicants and natural
compounds have been reported to bind and activate this receptor (2). The AHR is a
xenobiotic sensor and regulator of detoxification enzymes. It has additional cellular roles
including, but not limited to development, protein regulation and cell cycle control (3).
Thus, the AHR is considered to be a master regulator of cellular pathways. Wellcharacterized AHR ligands include a wide array of environmental contaminants such as
halogenated aromatic hydrocarbons (HAH) such as, 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) and polycyclic aromatic hydrocarbons (PAH) such as, benzo(a)pyrene (B(a)P)
(4,5). AHR ligands can vary dramatically in their chemical structures and include natural
products, endogenous and synthetic agents (6). Importantly, an endogenous ligand for the
AHR has not been firmly established. The AHR ligand also influences the regulatory
actions of the AHR on multiple cellular pathways (2,7,8). This study evaluated the effects
of α-tocopheryl quinone (TQ) and curcumin analog 27 (ca27) on AHR activity and
expression. The AHR is a regulator of multiple cellular pathways including AR
expression.
The androgen receptor (AR) is a ligand activated nuclear receptor that plays a
critical role in male development, fertility, sex accessory organ development and function
(9-11).

112

The AR is activated by androgens such as testosterone and its more active metabolite 5αdihydrotestosterone (DHT). The AR is required for the development and progression of
CaP (12). The activation of the AR is a major target in current prostate cancer
therapeutics in which the depletion of androgen and inhibition of AR activation are
primary strategies. Unfortunately, resistance to these therapies can occur and the
expression of the AR can still be retained and activated (13,14). TQ and ca27 downregulate AR protein expression and activate the AHR. In an effort to elucidate TQ and
ca27 mechanism(s) of inhibition, the potential action of the AHR on AR down-regulation
was examined.
Expression of the AHR, and its heterodimer partner ARNT, have been detected in
developing fetal prostate and the normal and malignant prostate of adult males (15,16).
The AHR has been shown to be an important regulator of prostate development in
multiple rodent models. Activation of the AHR by agents such as TCDD demonstrate
retardation of fetal and perinatal prostate development (15,17,18). However the role of
the AHR is dependent on the stage of development, species, cell-type and AHR ligand. In
2007, Fritz et al. (19) demonstrated that the AHR can act as a tumor suppressor in the
CaP developing mouse model, TRAMP. Wild-type, heterozygous and AHR null TRAMP
mice were evaluated for prostate cancer incidence, neuroendrocrine differentiation
markers and AR expression. Heterozygous and AHR null animals developed malignant
prostate tumors more frequently than wild-type (19). Several studies have begun to
identify the ligand-specific regulatory role that the AHR may have on AR activation,
expression and the role the AR may have on AHR activation. Activation of the AR by
DHT repressed AHR transcriptional activation upon treatment with the PAH, 3-
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methylcholanthrene (3-MC) (20). In contrast, activation of the AHR by 3-MC
demonstrated AHR’s novel activity as a ligand activated adaptor protein for E3 ubiquitin
ligases which led to proteasomal degradation of the AR (21). The interplay and regulation
between the AHR and AR is complex, with multiple components having to be taken into
consideration. TQ and ca27’s actions as potential AHR agonists may have consequences
resulting in AR down-regulation.
TQ and ca27 have previously been reported as anti-androgenic agents in human
CaP cells (Chapter 3) (22). TQ is the oxidative metabolite of VE, and has demonstrated
unique properties in comparison to VE (Chapter 3). TQ inhibits prostate cancer cell
proliferation, AR activation and AR expression. However, VE demonstrated no growth
inhibitory effects on CaP cells, AR activation or AR expression (Chapter 3). The
curcumin analog ca27 also demonstrated anti-androgenic activities similar to TQ.
However, its parent compound curcumin did not inhibit AR expression (Chapter 2) (22).
Both TQ and ca27 were found to be potent inhibitors of AR expression in comparison to
VE or curcumin. Although, both TQ and ca27 have anti-androgenic activities their
kinetics of AR down-regulation and effects on cell viability are very different between
the two agents. This study further elucidates TQ and ca27’s inhibitory actions on the AR
by evaluating their regulation of the AHR.
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Materials and Methods
Chemicals, cell culture, and treatment protocols
dl--tocopheryl quinone was obtained from Research Organics (Cleveland, OH). Ca27
was synthesized by Drs. Vander Jagt and Deck laboratory (Department of Biochemistry
and Molecular Biology and Department of Chemistry, University of New Mexico).
6,2’,4’-Trimethoxyflavone (TMF) and α-napthoflavone: 2-phenyl-4H-benzo(h)chromen4-one (α-NF) and other chemicals used in these studies were acquired from Sigma
Chemical Co (St. Louis, MO).
The LNCaP cells used in these studies were acquired from American Type Culture
Collection (Manassas, VA). Cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Carlsbad, CA) containing 5% heat-inactivated fetal calf
serum (FCS; Sigma, St. Louis, MO) with streptomycin-penicillin antibiotics (designated
DMEM/FCS) in a 5% CO2 incubator at 37C.
Messenger RNA expression analysis
Total RNA was extracted from cells using TRIzol Reagent (Invitrogen) and cDNA
was prepared from total RNA using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA). Quantitative PCR (qPCR) was performed for
mRNA levels using an Applied Biosystems 7900HT Fast Real-Time PCR System
(Carlsbad, CA) and QuantiTect Primers Assays (Qiagen Inc., Valencia, CA) GAPDH
mRNA. Additional forward and reverse primers include AHR forward 5’GCCAGGCCAACAGGCATTTTT-3’ and reverse 5’-GGTCTGGCTTCTGACGGATGA
TGA-3’, and CYP1A1 forward 5’-CCCAAGGGGCGTTGTGTCTTT-3’ and reverse 5’CAGGGGTGAGAAACCGTTCAG-3’.
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AR and AHR immunoblot analysis
LNCaP cells were plated at a density of 1106 cells per 100 mm cell culture plate
in 10 ml of DMEM/CSS and maintained in incubators at 37°C in 5% CO2. For doseresponse studies, LNCaP cells were cultured in 6-well plates (BD Biosciences, San Jose,
CA) in DMEM containing 5% FBS. After a 4 d treatment with vehicle, VE, or TQ, cells
were washed in cold 1 PBS and lysed in a buffer containing 1.0 % Igepal CA-630, 0.5
% sodium deoxycholate, 0.1 % sodium dodecyl sulfate, 0.1 mg/ml phenylmethylsulfonyl
fluoride, 1 mM sodium orthovanadate, and 10 µg/ml aprotinin in 1 PBS. Cell extracts
were stored at -80°C until analysis. Sample protein levels were determined using the
BCA Protein Assay kit (Pierce Biotechnology, Rockford, IL), according to kit
instructions. Total protein (≤ 40 µg) from cell extracts were electrophoresed on 12.5 %
SDS-polyacrylamide gels (BioRad, Hercules, CA) and transferred to Immobilon-P
membranes (Millipore Corp., Bedford, MA) using a GENIE wet transfer system (Idea
Scientific, Minneapolis, MN).

Membranes were blocked in Tris-buffered saline

containing 5% nonfat dry milk at 4°C and then incubated with mouse anti-AR (441)
monoclonal antibody) or mouse anti-AHR (A-3) (Santa Cruz Biotechnology, Santa Cruz,
CA) or mouse anti-β-actin antibody (A5441; Sigma). After washing, membranes were
incubated with a secondary horseradish peroxidase-conjugated goat anti-mouse IgG
(Biomeda, Foster City, CA) and analyzed using Western Lightening Chemiluminescence
Reagent Plus (Boston, MA) on a Kodak Image Station 4000MM (Rochester, NY). Band
intensities were determined using Kodak Molecular Imaging Software.
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Co-immunoprecipitation assays
AHR and AR proteins were isolated by co- immunoprecipitation. Cells were cultured
as described above and treated as described in the figure legends. Cells were harvested in
lysis buffer (20mM Tris, pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% triton X100, 2.5mM sodium pyrophosphate, 1mM β-glycerophosphate, 1mM sodium vanadate, 1
µg/ml leupeptin and 1mM PMSF), sonicated and centrifuges at 10,000rpm for 5min at
4˚C to remove cellular debris. Protein (500 µg/500µl) was incubated with 5µl of rabbit
polyclonal antibody (AR (Ab-2) Thermo-Scientific, Fremont, CA) for at least 1h at 4˚C,
then Protein A beads (Invitrogen, Carlsbad, CA) were added in a 1:1 slurry and samples
were incubated for an additional 1-2 h at 4˚C. The beads were recovered by
centrifugation at 10,000 rpm for 5min at 4˚C and washed five times with 1ml of lysis
buffer.
XRE reporter assay
LNCaP cells were cultured in 12- or 24-well plates (Invitrogen) in DMEM/CSS 2 d
before transfection. Xenobiotic-induced transcriptional activation was determined using a
reporter construct with a xenobiotic response element (XRE) (or DRE dioxin response
element) that regulates the expression of luciferase (23). Cells were co-transfected with
the XRE-Luciferase reporter plasmid and a control plasmid carrying a thymidine kinase
(TK) promoter regulating Renilla luciferase cDNA expression (Promega, Madison, WI)
using Lipofectamine 2000 transfection agent (Invitrogen, Carlsbad, CA). Fourty-eight h
post-transfection cells were treated with the indicated agents for 24 hours. Whole cell
extracts were generated using Cell Culture Lysis Reagent (Promega, Madison, WI).
Luciferase activity was measured using the Luciferase Assay Substrate kit (Promega,
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Madison, WI) and relative luciferase units determined on a Perkin Elmer Victor3V 1420
counter and analyzed using Wallac 1420 software (Perkin Elmer, Turku, Finland).
Normalized luciferase expression is expressed as a percent of vehicle control.
AHR RNAi assays
LNCaP cells were transfected with 20 nM siAHR or scrambled negative control
(siNC) (Ambion, Carlsbad, CA) using Hiperfect (Qiagen, Valencia, CA) following
manufacture protocol. Cells were transfected for 48 h, then treated with 25 µM TQ or 5
µM ca27 for the indicated times. RNA and protein were isolated and analyzed according
to the protocols described above.
Microarray Analysis
LNCaP cells were treated with BSA (vehicle control) or 30 µM TQ for 4 d.
Samples were processed following instructions provided by Affymetrix for the Human
Genome U1333A Plus 2.0 Gene Chip Array. Arrays were analyzed by UNM Keck-UNM
genome facility. Fold ratios were computed for TQ exposed cells compared to BSA
controls.
Statistical analysis
Significant differences in values between groups were assessed using an unpaired ttest with SigmaStat 3.1 software (Systat Software, Inc., San Jose, CA). P values less than
0.05 were used to signify statistical significance. Most studies were performed as
specified with a minimum of 3 samples (i.e., n 3) unless otherwise specified.
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Results
TQ and ca27 activate the AHR
In an effort to identify pathways important in the mechanism of TQ’s action on
CaP cells, microarray studies were performed using Affymetrix Human Genome U1333A
Plus 2.0 GeneChip arrays to examine alterations in gene expression induced by TQ. A
high ranked pathway modulated by TQ included xenobiotic metabolism pathways. An
increase in phase I and II metabolizing enzymes such as CYP1A1, aldoketoreductase 1C1
(AKR1C1), AKR1B10, glutamate-cysteine ligase, and AHR expression was observed
(Table 1). TQ demonstrated a time-dependent increase of AKR1C1 expression upon TQ
treatment in LNCaP cells (Fig. 1A). CYP1A1 was also significantly increased 15-fold
upon 25µM TQ after 24 h but there was no significant change upon 25µM VE treatment
(Fig. 1B). To determine ca27 effects on AHR-activation CYP1A1 mRNA expression was
measured. One µM ca27 significantly increased CYP1A1 expression after 12h in LNCaP
and C4-2 cells (Fig. 1C-D). Studies to further determine if TQ or ca27 modulated AHR
activity were initiated using a xenobiotic-response element (XRE) luciferase reporter
system in CaP cells. XRE reporter activity was assessed in PC3 cells after treatment with
25 µM TQ or VE for 24 h. TQ treatment significantly increased AHR activity in contrast
to VE, which had no detectable effect (Fig 1E). ca27 also significantly increased AHR
activity, but not with 10 µM curcumin after 12 h (Fig. 1F).
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Table 1. Up-regulation of AHR regulated genes by TQ.

1

AHR regulated genes1

Gene
Symbol

Accession
Number

(mRNA)
Fold
Increase2

Aldoketoreductase 1C1

AKR1C1

NM_001353

96.0

Cytochrome P450 1A1

CYP1A1

NM_000499

43.1

Aldoketoreductase 1B10

AKR1B10

NM_020299

24.0

Glutamate-cysteine ligase,
m-su

GCLM

NM_002061

4.9

Aryl Hydrocarbon
Receptor

AHR

NM_001621

2.2

AHR regulated transcripts identified from pathway profile analysis Microarray studies

were performed as described previously (Chapter 3). Arrays were analyzed by the UNM
Keck-UNM Resources facility.
2

Fold increases compared to vehicle control in LNCaP cells
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Fig. 1: TQ and ca27 activate the AHR in CaP cells. TQ activates the AHR as measured
by the AHR regulated transcripts CYP1A1 (A) and AKR1C1 (B) mRNA expression.
LNCaP cells were treated with vehicle control, 25uM VE or 25uM TQ for 48h (A) or 1121

4d (B). ca27 induces CYP1A1 expression in C4-2(C) and LNCaP (D) cells treated with 1
or 5uM ca27 for 12 and 24h. CYP1A1 and GAPDH mRNAs were measured by qRTPCR. TQ (E) and ca27 (F) activate the AHR, as measured by an AHR reporter assay.
Cells were co-transfected using a XRE reporter plasmid driving luciferase and thymidine
kinase reporter plasmid driving Renilla luciferase. * denotes P < 0.05 compared to
control.

TQ up-regulation of CYP1A1 and AHR expression is AHR dependent
The observation that TQ treatment induces AHR transcriptional activity, (Fig. 1)
led investigators to evaluate the AHR in modulating AHR and CYP1A1 expression. AHR
mRNA expression was knocked down using siRNA. LNCaP cells were transfected with
20 µM siAHR or siNC for 48 h and then treated with 25 µM TQ for 48 h. Samples
treated with siAHR showed a significant inhibition of AHR mRNA expression in
comparison to siNC (Fig. 2A). siNC samples treated with TQ showed a significant 8-fold
induction of AHR mRNA expression. This increase in expression was significantly
inhibited by AHR knock-down (siAHR) at both 48 h and 96 h time points. Twenty-five
µM TQ significantly increased CYP1A1 mRNA expression in a time dependent manner
in siNC controls. This induction was significantly attenuated by knock-down of AHR
expression at both time points tested (Fig. 2B). To further evaluate TQ’s induction of
AHR expression in LNCaP cells the levels of AHR mRNA were measured using qPCR
after treatment with 25 µM TQ for 96 h significantly increased AHR expression by 20fold (Fig. 2C). AHR protein levels were measured by immunoblot and normalized to
levels of β–actin protein after 96 h of 25 µM TQ treatment (Fig. 2D).
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Fig. 2: AHR expression is critical for TQ induction of CYP1A1. AHR expression was
knocked down using RNAi. (A+B) LNCaP cells transfected with 20 µM siAHR or
scrambled Negative Control (siNC) for 48 h and treated with 25 µM TQ for an additional
48 h, AHR, CYP1A1 and GAPDH mRNAs were measured by qRT-PCR. LNCaP cells
were also treated with 25 µM TQ or 25 µM VE for 4 d, AHR mRNA (C) and protein
expression (D+E). (E) Graph represents values of AHR protein expression normalized to
β-actin expression, * denote P < 0.05 compared to control.
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AHR agonist benzo(a)pyrene inhibits AR protein expression
To determine if AHR activation led to the proteasomal degradation of the AR in
human prostate cancer cells, cells were pretreated with 10 µM MG132 for 2 h and the
treated with 1 µM B(a)P in the presence of MG132 for 2 h. B(a)P significantly inhibited
AR protein expression. This inhibition of AR by B(a)P was significantly inhibited by the
proteasomal inhibitor MG132 (Fig. 3A-B). To determine if the AHR inhibited AR protein
expression upon activation two AHR antagonists were used, TMF and α-NF (24). LNCaP
cells were treated simultaneously with 25µM TQ and 10µM TMF or α-NF for 48 h. AR
protein levels were normalized to levels of β–actin protein, which was not affected by the
treatments. Graphs represent a n=2, therefore no statistical analysis were performed.
LNCaP cells treated with either TMF or α-NF (Fig. 3C-D) did not prevent TQ’s downregulation of the AR. To evaluate AHR inhibition upon ca27 treatment LNCaP cells were
treated simultaneously with 5µM ca27 and 10µM TMF or α-NF for 3 h. Neither, TMF or
α–NF prevented ca27 down-regulation of AR protein expression (Fig. 3E-F).
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Fig. 3: B(a)P inhibits AR protein expression, AHR antagonist do not rescue AR from
TQ or ca27. AHR activation leads to AR down-regulation can be rescued by proteasomal
125

inhibitor. (A+B) LNCaP cells were pretreated with 10uM MG132 for 2hrs and then 1uM
BaP for 2hrs. (C+D) LNCaP cells treated with 25 µM TQ in the presence or absence of
10 µM TMF or α-NF for 48 h. (E-F) LNCaP cells treated with 5µM ca27 and 10µM TMF
or α-NF for 3 h, AR immunoblots (C and E), and densitometry analysis (D and F) are
represented.* denote P < 0.05 compared to control.

AHR expression is not critical for AR down-regulation by TQ or ca27
To determine if TQ or ca27 increased AHR and AR protein interaction coimmunoprecipitation pull down assays were performed. LNCaP cells were treated with 5
µM ca27 or 25 µM TQ for the indicated times. AR and associated proteins were
immunoprecipitated using AR-specific antibody following described in the Materials and
Methods. Immunoblots were probed for AHR protein first, stripped and then probed for
AR protein expression. Cell lysates treated with TQ for 6 h demonstrate no difference
AHR/AR protein interaction in comparison to control (Fig. 4A-B). Cells treated with
ca27 demonstrate no difference in AHR/AR protein interaction after 15-45 min compared
to control (Fig. 4C-D).
To determine if TQ and ca27 activation of the AHR induced AR protein downregulation, AHR protein expression was knocked down using siRNA. LNCaP cells
transfected with 20 µM siAHR or scrambled Negative Control (siNC) for 48 h and
treated with 25 µM TQ for an additional 48 h. AHR and AR protein were measured by
WB and normalized to levels of β–actin protein. Knock-down of AHR protein expression
did not rescue AR expression upon TQ treatment (Fig. 5A-C). LNCaP cells were also
transfected with 20 µM siAHR and treated with 5uM ca27 for 3h. However, knock-down
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of AHR protein expression does not rescue AR expression upon ca27 treatment (Fig. 5DF).

Fig. 4: AHR and AR protein interaction is not modulated by TQ or ca27. LNCaP cells
were treated with 25 µM TQ (A-B) or 5 µM ca27 (C-D) or vehicle control for the
indicated times. AR and AHR were immunoprecipitated using AR-specific antibody.
Immunoblots were probed for AHR protein first, stripped and then probed for AR protein
expression, both immunoblots are represented.
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Fig. 5: Knock-down of AHR protein expression does not rescue AR expression upon TQ
or ca27 treatment. LNCaP cells were treated with siAHR or siNC (scrambled Negative
Control) and treated with 25uM TQ (A-C) for 2 d or with 5 µM ca27 for 3 h. AHR and
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AR protein was measured by WB and densitometric analysis (ratio AR:β-actin). * denote
P < 0.05 compared to control, # denote P < 0.05 compared to negative control.

Discussion
In this study we investigated the agents, TQ and ca27 as potential AHR activators
by evaluating AHR transcriptional activation and its role in AR down-regulation in CaP
cells. To begin identifying potential pathways activated upon TQ treatment, Affymetrix
Gene chip arrays were performed. Profile analysis from this study demonstrated
modulation of xenobiotic metabolic pathways (Fig. 1A). The AHR is a well-characterized
transcription factor that regulates expression of several detoxification and metabolizing
enzymes. The AHR may have alternative functions in the cell other than as a ligand
activated transcription factor. One alternative function of the AHR previously reported is
upon 3-MC activation, to act as adaptor protein for E3 ubiquitin-ligase complex
formation targeting the degradation of the AR (21). The increased expression of AHR
regulated transcripts and down-regulation of AR expression by TQ led us to further
evaluate the potential mechanism of AHR down-regulation of AR.
The AHR regulates the expression of several detoxification and metabolizing
enzymes including CYP1A1 and AKR1C1 (23,25). TQ induced the expression of both
AKR1C1 and CYP1A1 in a time-dependent manner and induced AHR activation as
measured by a XRE-reporter assay (Fig. 1). AHR activity was only significantly induced
by TQ, while VE demonstrated no effect. To determine if CYP1A1 induction was through
activation of the AHR, AHR expression was knocked down using RNAi. The increase in
CYP1A1 expression was significantly inhibited by AHR knock-down at both time points
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tested. Although expression of CYP1A1 was still significantly increased in siAHR treated
samples, this could be explained by residual AHR or transcription factor, such as LXR in
regulating its expression. The liver X receptor α has recently been demonstrated to be a
regulator of CYP1A1 mRNA expression (26). Regardless, CYP1A1 mRNA induction by
TQ is significantly repressed upon siAHR. This is the first study to demonstrate that TQ
can act as potential agonist ligand for the AHR.
The activation of the AHR by TQ led us to investigate ca27’s actions on the AHR.
ca27 significantly increased CYP1A1 expression in a time- and dose-dependent manner
and AHR activation as measured by a XRE-reporter assay. Although, ca27 induced AHR
activation it had differential effects on AHR expression in comparison to TQ. TQ induced
AHR mRNA and protein expression after 48 h. However, ca27 significantly inhibited
AHR protein expression after only 3 h. The differences between TQ and ca27 are also
demonstrated in their inhibition of AR protein expression. ca27 inhibits AR protein
expression within 3 h as a opposed to TQ which requires at least 48 h (22) (Chapter3).
TQ’s regulation of AHR expression is time dependent for both mRNA and protein levels.
The significant increase of AHR protein expression after 48 h is selective since AR
protein expression is significantly inhibited at this time. The regulation of AHR
expression induced by TQ has been demonstrated for specific AHR ligands such as
TCDD and 3-MC (27,28). This study provides support for the selectivity of TQ’s AR
down-regulation and begins to address additional questions regarding TQ’s regulation of
AHR expression. In this study, we have begun to demonstrate TQ’s potential role as a
ligand for the AHR.
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The PAH B(a)P has previously been shown to inhibit AR protein expression in
human lung adenocarcinoma cell line (29). The study conducted by Lin et al. (29) tested
B(a)P and TCDD mediated down-regulation of the AR. TCDD did not significantly
inhibit AR protein expression as opposed to B(a)P (29). In 2007, Ohtake et al. (21)
demonstrated 3-MC activated AHR was a component of a ubiquitin ligase complex
which regulated AR degradation. To address if activation of the AHR by a known agonist
such as B(a)P could induce AR degradation in human CaP cells, cells were treated with
the AHR agonist B(a)P in the presence of the proteasomal inhibitor MG132. B(a)P
significantly led to AR protein degradation which could be prevented by MG132. The
environmental contaminant B(a)P may act as an endocrine disruptor through modulation
of AHR activity leading to AR degradation in human CaP cells.
To further study AHR activity on AR protein inhibition, two AHR antagonists
TMF and α-NF treated in the presence or absence of TQ or ca27 were used (24,30-32).
These antagonists did not significantly prevent AR down-regulation upon ca27 treatment.
However, treatment with TMF and α-NF did demonstrate an attenuation of AR downregulation upon TQ treatment. The potential role of the AHR as an adaptor protein for
AR degradation may require an increase in AHR and AR interaction. To determine if TQ
and ca27 increased the interaction between AHR and AR co-immunoprecipitations were
performed. However, neither agent dramatically increased this interaction at the times
tested. To further evaluate the role of the AHR upon AR down-regulation by TQ and
ca27, AHR expression was significantly reduced by siRNA. This inhibition of AHR
expression did not prevent TQ or ca27’s down-regulation of AR protein expression
suggested that the AHR is not a critical component of TQ or ca27 mechanism of AR
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down-regulation. TQ and ca27 regulate the expression of the AHR in distinct ways. ca27
increases AHR activation and inhibits AHR protein expression within 3 h. TQ regulates
AHR expression in a time–dependent manner and induces the expression of CYP1A1
through an AHR mediated mechanism. Although TQ’s down-regulation of the AR is not
mediated by the AHR, TQ’s regulation of the AHR expression demonstrates specificity
for AR down-regulation and provides a potential mechanism of TQ’s actions on
activating xenobiotic metabolism pathways.
We conclude that both TQ and ca27’s activation of the AHR is not a major
component in their mechanism of AR down-regulation. Further, TQ’s induction of
CYP1A1 expression is AHR dependent suggesting that TQ may be an agonist for the
AHR and regulator of AHR expression. In comparison to VE which did not induce
CYP1A1 expression, TQ modulates distinct cellular pathways such as activation of the
AHR and down-regulation of AR protein expression. Although, the activation of AHR by
TQ, may be independent of AR protein down-regulation, this study provides evidence of
TQ’s actions on AHR activation, AHR expression and AHR-dependent induction of
CYP1A1 in human CaP cells.
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CHAPTER 5: SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS

Summary
Identifying the actions of agents that inhibit androgen receptor (AR) protein
expression may elucidate novel mechanism(s) for targeted therapeutics. The expression
and activation of the AR is critical for the development of male characteristics and
fertility (1). However, abnormal AR activity and/or expression can also lead to various
disease etiologies. For example, the AR plays a critical role in normal prostate
development and function. However, it also plays a major role in the development and
progression of prostate cancer (2). Therefore, the activation of the AR is a major target in
current prostate cancer therapeutics in which the depletion of androgen and inhibition of
activation are primary therapeutic strategies. Unfortunately, resistance to androgen
ablation therapies can occur and expression of the AR can still be retained and activated
in CaP (3,4). In this work, two novel agents, curcumin analog 27 (ca27) and alphatocopheryl quinone (TQ) were identified, as potent anti-androgenic agents. Both agents
inhibit prostate cancer (CaP) cell proliferation, AR activation (i.e. PSA and ARRE
reporter assay), and AR expression. In this dissertation respectively, significant progress
was made to identify the mechanism(s) of ca27- and TQ-mediated AR down-regulation.
Agents that induce AR reduction not only provide a means to elucidate molecular
mechanisms of AR down-regulation, but also significantly contribute to experimental
therapeutic strategies for CaP.
ca27 is an analog of the natural product, curcumin (5). In Chapter 2 (6), studies
illustrating ca27’s anti-androgenic properties were presented. ca27 inhibits CaP cell
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proliferation, viability and AR protein expression. ca27’s chemical structure (Chapter 2,
Fig. 1) consists of two phenolic rings with symmetrical ortho-hydroxyl groups and a 5carbon unsaturated linker with a single carbonyl group (Chapter 2, Fig. 1). The carbon
linker retains the character of an α,β-unsaturated ketone which has properties of a
Michael acceptor, a strong electrophile (7,8). Michael acceptors bind and deplete
nucleophilic groups such as free thiols.. The mucolytic agent NAC, is also a thiol and a
precursor of reduced glutathione (9-11). ca27 increases ROS production, and
electrophilic or antioxidant responsive genes (6). ca27 down-regulates AR protein
expression and the addition of NAC attenuates ca27’s down-regulation of the AR.
Results from my dissertation indicate that ca27’s mechanism of AR down-regulation
involves pro-oxidant activity.
TQ is the oxidative metabolite of vitamin E (VE) and has distinct properties from
VE. TQ is a quinone which induces cellular redox cycling through Michael addition
reactions; this activity is in contrast to VE’s antioxidant activities. In Chapter 3, results
illustrating TQ’s anti-androgenic activity and down-regulation of AR protein expression
are presented. VE on the other hand, did not inhibit AR activation or AR protein
expression. TQ’s down-regulation of AR protein expression was independent of mRNA
inhibition or proteasomal degradation (Chapter 3). To further elucidate TQ’s actions on
the AR and the potential activity of TQ as a quinone, oxidative stress pathways were
evaluated. TQ significantly increased total and oxidized glutathione levels indicating
oxidative stress. Further, TQ increased the expression of antioxidant regulated transcripts,
induced ER stress and activated the UPR. The induction of oxidative stress by TQ leads
to AR protein down-regulation and the presence of antioxidants such as NAC and VE
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prevent this down-regulation. TQ’s mechanism of AR down-regulation its through is
activity as a pro-oxidant. TQ’s actions on AR protein expression are distinct from VE and
the differences reported begin to provide insight into the differences in their potential
mechanism(s) regulating AR expression.
In an attempt to identify TQ and ca27’s mechanism(s) of AR protein downregulation, the role of the AHR was investigated. A microarray conducted on TQ treated
LNCaP cells, revealed a profile that the AHR pathway was activated. Ohtake et al. (12)
reported that the ligand activated AHR could induce proteasomal degradation of the AR.
To determine the AHR’s role on the AR, cells treated with the AHR agonist B(a)P had
significantly reduced AR protein expression. AR protein down-regulation upon AHR
activation was prevented by the proteasomal inhibitor MG132. Although TQ and ca27
induced the activation of the AHR (i.e. using a XRE reporter assay and evaluating
CYP1A1 mRNA expression) the knock-down of AHR expression did not prevent AR
down-regulation by either agent. To determine if the induction of CYP1A1 expression
was dependent on the AHR, expression of AHR was knocked-down and upon treatment
with TQ there is a significant attenuation of CYP1A1 expression. This study demonstrates
TQ induces AHR transcriptional activation resulting in the increased expression of
CYP1A1. Both TQ and ca27 induce AHR transcriptional activation; however, AHR
activation is not a critical factor in TQ or ca27’s mechanism of AR down-regulation.
TQ and ca27 both inhibit CaP cell proliferation, AR activation and AR protein
expression. TQ and ca27 down-regulate AR protein expression independent of
transcriptional or proteasomal inhibition. Both agents increase AHR activity but this
activation is independent of AR down-regulation. Although TQ and ca27 have distinct
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cellular consequences results from my studies support that both agents down-regulate AR
protein expression through an oxidative stress mediated mechanism. The results of these
studies may provide insight into the development of AR targeted therapeutic strategies
through the identification of TQ and ca27’s mechanism(s) of action.

Key accomplishments


Determined that ca27 dose-dependently inhibits CaP cell proliferation and
viability



Determined that TQ inhibits CaP cell growth but does not inhibit cell viability up
to 4 days of treatment
o Determined kinetic differences of ca27 and TQ inhibition of AR activity
o ca27 inhibits AR activity in ≤ 24 hours while TQ requires ≥ 48 hours



Determined kinetics and doses required for down-regulation of AR expression
o AR mRNA down-regulation is inhibited by ca27 within 3 hours, while TQ
requires ≥ 48 hours
o TQ inhibits AR protein expression ≥ 48 hours versus ca27 that requires 3
hours for AR protein down-regulation



Evaluated potential mechanism(s) for AR protein down-regulation by ca27 and
TQ
o Determined AR protein down-regulation is independent of AR
transcriptional inhibition for TQ and ca27
o Determined TQ and ca27’s AR down-regulation is independent of
proteasomal degradation
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o Determined both agents induce AHR activation but AR down-regulation
is independent of the AHR


Determined both agents modulate cellular reduction/oxidation parameters
o ca27 increased ROS generation and induced the expression of antioxidant
regulated genes within 1-3 hours
o TQ increased total and oxidized glutathione levels and induced the
expression of antioxidant regulated transcripts
o TQ induced ER stress leading to activation of UPR signaling cascades by
4 days



Elucidated a potential mechanisms involved in TQ and ca27’s down-regulation of
AR protein expression involving cellular reduction/oxidation events
o ca27 down-regulation of AR protein expression is attenuated by the
antioxidant NAC within 3 hours
o TQ down-regulation of the AR protein expression was attenuated by both
NAC and VE within 48 hours
o TQ down-regulation of AR protein expression was potentiated by the
glutathione synthesis inhibitor BSO within 48 hours



Determined both agents induce AHR activation but this activity was independent
of AR down-regulation
o Demonstrated that ca27 induces AHR activity (i.e. using a XRE reporter
assay and evaluating CYP1A1 mRNA expression)

142

o Determined that the knock-down of AHR expression did not prevent ca27
down-regulation of AR protein expression
o Demonstrated TQ induces AHR activity (i.e. using a XRE reporter assay
and evaluating CYP1A1 mRNA expression)
o Determined that the knock-down of AHR expression did not prevent TQ
down-regulation of AR protein expression
o Demonstrated that TQ induces CYP1A1 expression in an AHR dependent
manner

Conclusions
In these dissertation studies to elucidate pathways involved in ca27 and TQ
mechanism of action in human CaP cells, their anti-androgenic and pro-oxidant activities
were the focus of investigation (Chapters 2-3) (6). The overriding goal of this project was
to identify novel pathways for targeting AR expression. The inhibition of the AR is an
established target for CaP therapeutics. ca27 and TQ were found to down-regulate AR
protein expression in a time- and dose-dependent manner. Although these agents are
similar in down-regulating the AR, their differences in this inhibition and other cellular
stress pathways provides insight into mechanisms regulating AR expression. Two of the
major differences between ca27 and TQ were potency and kinetics of AR downregulation. A potential explanation may be the capacity of our agents to act as prooxidants. Intriguingly, the results in this dissertation demonstrate a similar mechanism of
AR down-regulation mediated by ca27 and TQ. ca27 and TQ down-regulate AR protein
expression though modulation of cellular redox. The attenuation of ca27’s and TQ’s
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down-regulation of AR expression by antioxidants provides further support that
modulation of cellular redox can lead to AR down-regulation in CaP cells. Therefore, I
conclude that perturbations in cellular redox by agents such as ca27 or TQ can be an
effective means of targeting AR down-regulation.
One of the differences between ca27 and TQ is ca27’s rapid down-regulation of
AR protein expression (i.e, 3 hours). ca27 was identified as a potential anti-androgenic
agent due to its inhibition of CaP cell proliferation, viability, AR activity and AR
expression. The potential reactivity of ca27 may be due to the chemical moieties within
its structure. ca27’s structure consists of a hydroxyl group at the ortho-positions on both
the aryl rings. Dinkova-Kostova et al. (13) demonstrated the importance of these orthopositioned hydroxyl groups as important moieties for the potent induction of NQO1
enzymatic activity and reactivity with sulfhydryl groups (13). The α,β-unsaturated
carbonyl group and the ortho-hydroxyl positioned groups on the aryl rings are highly
reactive moieties that are most likely responsible for the rapid pro-oxidant and cytotoxic
responses observed by ca27 in these studies. The potential reactivity of ca27’s structure
as a potent electrophile is supported by the increase in ROS generation and the activation
of the Nrf2 pathway (Chapter 2). ca27 treatment increased the expression of antioxidant
response element regulated transcripts such as NQO1. ca27’s down-regulation of AR
protein expression was determined to be, for the most part, independent of AR mRNA
expression and proteasomal degradation. ca27 also induced activation of the AHR and
increased expression of the detoxification enzyme CYP1A1. Although the AHR has
previously been reported to regulate AR expression, down-regulation of the AR by ca27
was independent of the AHR. To determine if ca27 induced oxidative stress resulted in
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AR protein down-regulation the antioxidant NAC was used. Treatment with NAC
attenuated ca27 down-regulation of AR protein expression. Although the induction of
oxidative stress is a general cellular response, there is a relative selectivity in ca27’s
actions on the AR. Pro-oxidants such as hydrogen peroxide did not inhibit AR protein
expression (Appendix V). This study demonstrates for the first time ca27’s regulation of
AR protein, AHR activation and induction oxidative stress (Model 1). ca27 induces ROS
generation, the expression of antioxidant response element regulated transcripts and
down-regulates AR protein expression through an AHR independent oxidative stressmediated mechanism. The conclusion is drawn that ca27 down-regulates AR protein in
CaP cells through a cellular redox-mediated mechanism.
The anti-androgenic activities of TQ were evaluated in this study. TQ inhibited
androgen-responsive CaP cell proliferation, AR activity and AR expression. TQ is the
oxidative metabolite of VE; however, VE had no inhibitory effects on CaP cell
proliferation or the AR. TQ contains a quinone structure and quinones can undergo redox
cycling leading to toxicity. α-TQ has distinct chemical properties that are unique in
comparison to other quinones such as γ- and δ-TQ. In general, quinone structures are
found to be toxic due to the electrophilic carbon centers present in the quinone structure
that are reactive to nucleophiles such as sulfhydryl groups. α-TQ did not have a
significant effect on cell viability (Appendix IV). However, TQ increased total
glutathione levels and increased oxidized glutathione, indicating oxidative stress. In
addition, TQ selectively inhibited AR protein expression in a time- and dose-dependent
manner. The inhibition of AR protein expression was at least in part, independent of
mRNA expression and proteasomal degradation. TQ treatment also induced the
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activation of the AHR and regulated AHR expression. Further, TQ increased expression
of the AHR regulated transcript CYP1A1 in an AHR dependent manner. Demonstrating
TQ may be a novel ligand/agonist of the AHR. Although TQ induced AHR activation
this was independent of its mechanism of AR down-regulation. To determine if TQ’s prooxidant activity was leading to AR down-regulation two antioxidants were used. NAC, a
glutathione precursor and the antioxidant VE both attenuated AR down-regulation by TQ.
This regulation of glutathione levels by NAC and VE may be a mechanism of attenuating
TQ’s actions on the AR. VE is believed to act primarily as an antioxidant, reducing
cellular oxidative damage produced by oxidized lipids (14,15). There is emerging
evidence that VE may be playing an alternative antioxidant role through the regulation of
glutathione expression (16,17). In a study conducted by Yamagata, K, et al. (16) VE
increased glutathione levels and expression of γ-GCS mRNA expression in rats (16). To
determine if the depletion of reduced glutathione levels were responsible for TQ’s down–
regulation of the AR the glutathione inhibitor BSO was used. BSO potentiated TQ’s
down-regulation of AR protein expression. Demonstrating TQ’s modulation of
glutathione homeostasis, at least in part, leads to AR protein down-regulation. This study
was the first to elucidate α-TQ pro-oxidant anti-androgenic activity and the contrast in
TQ’s activity in comparison to VE. And demonstrate TQ’s induction of CYP1A1
expression is through an AHR mediated mechanism. TQ has unique inhibitory activities
in CaP cells in comparison to VE, TQ down-regulates AR protein expression potentially
through the modulation of reduction potential, and this down-regulation is independent of
AHR activation. In conclusion, the identification of TQ’s actions provides an explanation
for the differences reported between TQ and VE. Additionally, TQ’s mechanism of
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action may be exploited for development of agents selectively targeting AR downregulation. Therefore, the conclusion is drawn that TQ down-regulates AR protein in CaP
cells through a cellular redox-mediated mechanism.
The agents tested, TQ and ca27 inhibit androgen-sensitive prostate cancer cell
proliferation, AR activation and AR expression. Determining the mechanism by which
our agents inhibit AR protein expression has revealed the importance of cellular redox
and has begun to elucidate its role in AR expression. Therefore, these studies provide
novel insights into molecular mechanisms regulating AR expression and identify
mechanisms to effectively target the AR. The mechanisms identified in these studies
provide a foundation for the development of AR targeted therapeutics.

Fig. 1: - Model of ca27’s mechanism of AR down-regulation.
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Fig. 2: Model of TQ’s mechanism of AR down-regulation.

Future Directions
Our studies begin to address how the agents TQ and ca27 down-regulate AR
protein expression in human CaP cells. I have presented that both of these agents induce
oxidative stress and that this stress is partially alleviated by the presence of antioxidants
such as NAC. In addition, I show that the induction of selective cell stress pathways such
as detoxification and ER stress pathways are induced by these agents. This section will
focus on additional questions that arose from these studies and provide suggestions for
addressing these questions.
The hypothesis driving this study was; AR protein down-regulation by small
molecules act through targetable molecular pathways.

148

To begin addressing the hypothesis, two small molecules were identified, TQ and
ca27 through an anti-androgenic activity screening procedure. TQ and ca27 were found
to inhibit CaP cell proliferation, AR activation and AR expression. They were found to
inhibit both AR mRNA and AR protein expression in CaP cells. To determine the
mechanism(s) of TQ and ca27’s down-regulation of AR protein expression, several
potential pathways were evaluated including AR transcriptional inhibition, proteasomal
degradation, and the activation of the AHR leading to AR down-regulation. In brief, the
results from these studies demonstrated that AR down-regulation by TQ and ca27 was
independent of these mechanisms. Due to the potential reactivity of some of the chemical
moieties within the structures of TQ and ca27, studies ensued to determine the effects of
TQ and ca27 on cellular redox changes. The results from these studies demonstrated the
induction of oxidative stress by TQ and ca27. To determine if the increase in cellular
oxidative stress led to the down-regulation of AR protein expression, cells were treated
with either TQ or ca27 in the presence of the antioxidant NAC. NAC significantly
prevented the down-regulation of AR protein expression by TQ or ca27. These studies
demonstrate that TQ and ca27 down-regulate AR protein expression at least in part
through the induction of oxidative stress pathways.
Future hypothesis: Molecular oxidative stress pathways have a regulatory role on
AR protein maturation and activity.
Both TQ and ca27 increase the expression of the antioxidant (i.e., electrophile)
response regulated transcripts. The expression of these transcripts is through the
activation of Nrf2. Although I measured Nrf2 activity through a reporter assay and
examined known regulated genes, these methods were indirect. Validating the direct
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interference of Nrf2 transcriptional activity with an electromobility shift assay (EMSA)
would be essential in determining if these agents directly lead to Nrf2 transcriptional
activity. It would also be important to determine if both TQ and ca27 lead to the
increased activity of NQO1. Previous studies support that indeed both our agents induce
NQO1 activity (13,18). However, it would be meaningful to determine if their downregulation of the AR is potentiated by inhibition of NQO1 activity. Targeting NQO1
expression through knock-down experiments would begin to address how important the
role of NQO1 is in the activity of these agents.
It is plausible that TQ’s actions on the AR are due to its potential activity as an
arylating electrophile. It has been reported that all three TQs (α-, γ-, δ-TQ) are redox
cycling compounds but only the partially methylated quinones (γ- and δ-TQ) are
arylating electrophiles that can lead to Michael adduct formation, which yield covalent
bonds with nucleophiles such as cysteinyl thiols (19,20). It would be useful to determine
if TQ directly binds to the AR and thus leads to adduct formation; or, if TQ’s effects are
more general, thus leading to cytotoxicity at later time points. Also, determining if other
arylating electrophiles such as, γ-TQ or δ-TQ, inhibit AR protein expression in this series
of experiments. In addition, determining if TQ’s structure is modified or converted to the
more potent γ-TQ through metabolism of α-TQ would provide further understanding of
TQ’s biological actions.
ca27 and TQ inhibit AR protein expression in a potentially transcriptional and
proteasomal independent manner. Determining if ca27 and TQ increase AR protein turnover by a pulse-chase assay would begin to address their role in AR translation. With the
sensitivity of the ER and corresponding chaperones to cellular redox potential, inhibition
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of proper AR translation and folding may occur upon treatment with these agents. The
ER is sensitive to redox transitions within the cell, due to the proper folding required by
its retained chaperones. The thiol redox state within the ER has a much lower
GSH/GSSG ratio than that found in the cytoplasm (21). This redox potential is optimal
for disulfide bond formation and perturbations of this ratio can lead to ER stress. Protein
disulfide isomerase (PDI) is essential in catalyzing disulfide bond formation and sensitive
to changes in ER thiol redox potential (21,22). Therefore, TQ’s pro-oxidant activity and
modulation of GSH expression may induce ER stress and this activation may be
attenuated by the presence of NAC.
The ER is a subcellular organelle in which secretory and membrane bound
proteins are folded, stabilized by disulfide bonds, post-translationally modified
(glycosylation), oligomerized and exported (19,23). The ER has a limited capacity to
process proteins and the accumulation of misfolded proteins, redox or ionic changes
within the ER lumen can lead to ER stress. The biological response to ER stress is
activation of the UPR. The UPR mediates its effects through three ER transmembrane
stress sensors PERK, IRE1 and ATF6 (23,24). Upon accumulation of misfolded proteins,
ER chaperones bind and retain these proteins to prevent their aggregation and formation
of large insoluble complexes (25). GRP78 (BiP) a HSP70 family member, represses
PERK, IRE1 and ATF6 activity until the accumulation of misfolded proteins and then it
releases the three sensors. The activation of these three UPR signaling cascades leads to
the time-dependent increased expression of several transcripts including ATF4, p58 IPK,
XBP-1 (spliced), ATF6 and CHOP (Fig 3). I demonstrated that TQ treatment leads to the
significant increased expression of these transcripts (Chapter 3). In identifying potential
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pathways activated upon TQ treatment, gene expression profiles were generated from
existing TQ microarray data (Appendix I). These profiles showed all three pathways were
activated, but to focus my efforts, I evaluated the potential role the PERK pathway may
be playing on TQ’s down-regulation of the AR.
In 2008, Ogawa et al. (26) demonstrated γ-TQ’s induction of glutathione (GSH)
levels was dependent on the activating transcription factor 4 (ATF4). ATF4 is an
important basic leucine zipper transcriptional regulator of the eukaryotic initiation factor
(eIF2α) kinase pathway (26). PERK is a transmembrane serine/threonine kinase that
phosphorylates eIF2α and Nrf2 (27,28). Phosphorylation of eIF2α attenuates translation
initiation of most transcripts while increasing translation of select mRNAs such as ATF4
(29). The inhibition of translation has a two-fold cytoprotective function. First, the
attenuation of protein synthesis prevents the further accumulation of misfolded or
unfolded proteins. Second, this inhibition of protein synthesis results in the decreased
consumption of reducing equivalents required for disulfide bond formation. PERK’s
additional regulation of cellular redox is the phosphorylation of Nrf2, resulting in the
increased regulation of detoxifying enzymes (30) and the regulation of ATF4 which can
increase GSH levels (26). Interference with this signaling pathway could prevent the
downstream antioxidant affects. eIF2α translational inhibition can be inhibited by the
selective dephosphorylation inhibitor salubrinal (31). We demonstrate that treatment with
TQ in the presence of salubrinal significantly potentiates its down-regulation of AR
protein expression (Appendix II). However, knock-down of PERK did not prevent TQ’s
down-regulation of AR protein expression (Appendix II). Therefore, PERK is not a
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critical factor in TQ’s actions on the AR but may be playing a protective role against
TQ’s pro-oxidant activities.
One of the most up-regulated transcripts in response to ER stress is GRP78, but I
did not observe this increase in my experiments. However, GRP78 is a HSP70 family
member, another member HSP70B’ is increased ~200 fold upon TQ treatment (Appendix
I). Several other chaperones that may be playing a role in AR’s proper folding are also
increased according to the profiles generated by our microarray data. Hip/p48 (HSC 70
interacting protein and HSP70 co-chaperone) was inhibited upon TQ treatment according
to our microarray profile data (Appendix I). Hip plays a major role in the initial stability
of the AR with its intermediate chaperone complex for efficient folding (32). The correct
folding of steroid hormone receptors into a ligand competent state may occur through an
assembly line process that involves specific chaperones, HSP70 (HSC70), HSP40 (Ydj1),
HOP (p60), HSP90 and Hip for these initial folding steps (32,33). Several HSP family
members are modified in their expression upon TQ treatment, which may reduce AR
proper folding. The induction of the PERK signaling cascade by TQ could lead to
changes in chaperone gene profiles which prevent the proper folding of AR. TQ’s
significant down-regulation of the AR occurs within 48 hours, but I do not demonstrate
the induction of UPR until later time points. TQ may be exerting its inhibition of existing
AR protein through oxidative stress, but it inhibits AR de novo synthesis through the
induction of ER stress pathways.
TQ and ca27 may serve as lead compounds. Both agents need to be validated in
vivo for their bioavailability, potential cytotoxicity and down-regulation of AR protein
expression. Although, we have begun to identify the mechanism(s) by which these agents
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inhibit AR protein expression further investigation into their potential reactivity in vivo
needs to be determined. The potential reactivity of both TQ and ca27 raises concerns for
the selectivity of their actions. These agents contain chemical moieties that are
electrophilic in nature and determining their relative selectivity of AR down-regulation in
vivo is required for their advancement.
TQ and ca27’s inhibition of AR protein expression through their pro-oxidant
activities demonstrates a novel mechanism for targeting the AR. The critical role the AR
plays in the etiology of various diseases make it a meaningful target for the prevention
and treatment of these diseases. My dissertation studies serve as a paradigm in
experimental therapeutics that may provide insight into the development of AR targeted
therapeutic strategies and a foundation for future studies in defining TQ and ca27’s
mechanism(s) of action.
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Fig. 3: – The three arms of the UPR signaling cascade; PERK, IRE1 and ATF6. Image
adapted from Ref 25.
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Fig. 4: Model for future directions identifying mechanisms of ca27’s down-regulation of
AR.

Fig. 5: Model for future directions identifying mechanisms of TQ’s down-regulation of
AR.
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APPENDIX I: TQ Induces Activation of the Unfolded
Protein Response Signaling Cascade
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Table 1. TQ induces the signaling cascades of the unfolded protein response (UPR)

1

UPR
regulated
genes1

Expression
Level (Fold
Change)2

Accession
Number

Function

IRE1

11.47

NM_001433

endoplasmic reticulum
to nucleus signalling 1

ATF6

4.579

NM_007348

activating transcription
factor 6

CHOP

5.637

BC003637

DNA-damage-inducible
transcript 3

GADD34

3.519

NM_014330

protein phosphatase 1,
regulatory (inhibitor)
subunit 15A

EDEM

2.755

AW139300

ER degradation
enhancing alpha
mannosidase-like

ERdj4

3.148

NM_012328

DnaJ (Hsp40) homolog,
subfamily B, member 9

ERdj5

3.482

BG168666

ER-resident protein
ERdj5

ATF3

17.78

AB078026

activating transcription
factor 3

UPR regulated transcripts identified from pathway profile analysis Microarray studies

were performed as described previously (Chapter 3). Arrays were analyzed by the UNM
Keck-UNM Resources facility.
2

Compared to vehicle control in LNCaP cells

164

Table 2 TQ induces XBP-1 regulated transcripts. XBP-1 transcriptional activation is
regulated by the IRE1 pathway.

1

XBP-1
Regulated
Genes1

Expression
Level2

Accession Number

Function

ERdj4

3.148

NM_012328

P58IPK

2.882

NM_006260

Herp2

9.374

NM_012258

EDEM

2.755

AW139300

DnaJ (Hsp40)
homolog,
subfamily B,
member 9
DnaJ (Hsp40)
homolog,
subfamily C,
member 3
hairy/enhancerof-split related
with YRPW motif
1
ER degradation
enhancing alpha
mannosidase-like

XBP-1 regulated transcripts identified from pathway profile analysis Microarray studies

were performed as described previously (Chapter 3). Arrays were analyzed by the UNM
Keck-UNM Resources facility.
2

Compared to vehicle control in LNCaP cells
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Fig. 1. TQ’s down-regulation of AR protein expression is potentiated by the eIF2α
inhibitor salubrinal. LNCaP cells were treated for 48 h with 25 µM TQ or vehicle control
(BSA) in the presence or absence of 10 µM salubrinal. Top panel represents immunoblots
of AR and β-actin expression. Graph represents values of AR protein expression
normalized to β-actin expression, * denote P < 0.05 compared to control.
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Fig. 2. Knock-down of PERK expression does not prevent TQ’s down-regulation of AR
protein expression. PERK expression was knocked down using RNAi. LNCaP cells
transfected with 40 µM siPERK or scrambled Negative Control (siNC) for 48 h and
treated with 25 µM TQ for an additional 36 h, AR protein expression was determined by
immunoblot. Top panel represents immunoblots of AR and β-actin expression. Graph
represents values of AR protein expression normalized to β-actin expression, * denote P
< 0.05 compared to control.
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APPENDIX II: TQ Modulates Various Chaperones
Expression
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Table 1. TQ modulates expression of multiple chaperone transcripts.

Chaperone
Genes1

Expression Level
(Fold Change)2

Accession
Number

Function

HSPA6

386.7

NM_002155

heat shock 70kDa
protein 6 (HSP70B')
Human heat-shock
protein HSP70B'
gene
DnaJ (Hsp40)
homolog, subfamily
B, member 9

HSP70B

75.78

X51757cds

MDG1; ERdj4;
MST049; MSTP049

3.148

NM_012328

P58; HP58; PRKRI;
P58IPK

2.882

NM_006260

DnaJ (Hsp40)
homolog, subfamily
C, member 3

GBP; FLJ20539;
HSPA5BP1

0.354

NM_017870

heat shock 70kDa
protein 5 (glucoseregulated protein,
78kDa) binding
protein 1

HIP1

0.497

AU145049

Huntingtin
interacting protein 1

1

Protein chaperone transcripts identified from pathway profile analysis Microarray

studies were performed as described previously (Chapter 3). Arrays were analyzed by the
UNM Keck-UNM Resources facility.
2

Compared to vehicle control in LNCaP cells
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Fig. 1. TQ induces the expression of HSPA6 (HSP70B’). LNCaP cells were treated with
25 µM TQ or vehicle control for 48-96 h. HSPA6 and GAPDH mRNAs were measured
by qRT-PCR. Graph represents values of HSPA6 mRNA expression normalized to
GAPDH expression. * denote P < 0.05 compared to control.
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APPENDIX III: TQ Does Not Reduce Cell Viability in
Androgen Responsive Prostate Cancer Cells
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Fig. 1. TQ does not inhibit cell viability in LNCaP and LAPC4 cells after 96 h. LNCaP
and LAPC4 cells were treated with 5-25 µM TQ or vehicle control for 96 h. Cells
viability was determined by total cell counts and trypan blue positive cell counts
respectively. Cell viability is expressed as percent of control.
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APPENDIX IV: Reducing Agent DTT or Pro-oxidant
H2O2 Do Not Inhibit Androgen Receptor Protein
Expression in Prostate Cancer Cells
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Fig. 1. TQ’s down-regulation of AR protein expression is not attenuated by DTT. LNCaP
cells were pretreated with 1 mM DTT for 24 h and then treated with 25 µM TQ or
vehicle in the presence or absence of 1 mM DTT for an additional 48 h. Top panel
represents immunoblots of AR and β-actin expression. Graph represents values of AR
protein expression normalized to β-actin expression, * denote P < 0.05 compared to
control.
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Fig. 2. H2O2 does not down-regulate AR protein expression at 100 µM for 3 h. LAPC4
cells were treated with 1, 10, 100 µM or vehicle control for 3 h. Top panel represents
immunoblots of AR and β-actin expression. Graph represents values of AR protein
expression normalized to β-actin expression, * denote P < 0.05 compared to control.
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APPENDIX V: ca27 Induces Glucocorticoid Receptor
mRNA Expression in Prostate Cancer Cells
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Fig. 1. ca27 induces glucocorticoid receptor (GR) mRNA expression in LNCaP cells.
LNCaP human CaP cells were treated with vehicle control of 1 µM or 5 µM ca27 for 12
and 24 h. GR and GAPDH mRNAs were measured by qRT-PCR. Graph represents
values of HSPA6 mRNA expression normalized to GAPDH expression. * denote P <
0.05 compared to control.
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Fig. 2. ca27 induces glucocorticoid receptor (GR) mRNA expression in C4-2. C4-2
human CaP cells were treated with vehicle control of 1 µM or 5 µM ca27 for 12 and 24 h.
GR and GAPDH mRNAs were measured by qRT-PCR. Graph represents values of
HSPA6 mRNA expression normalized to GAPDH expression. * denote P < 0.05
compared to control.
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